2019-11-14T09:55:49-06:00 2018-12-31 ERNST & YOUNG US LLP 111 MONUMENT CIRCLE SUITE 4000 INDIANAPOLIS IN 46204 990 2018-01-01 912154267 Memorial Sloan-Kettering Cancer Center % MARK K SVENNINGSON MEMO 6462273092 1275 York Avenue New York NY 10065 MARK K SVENNINGSON SVP FINANCE 6462273092 2019-11-14 true JENNIFER D RHODERICK P00395735 3176817000 108.206.163.59 35057220193185000004 2019-11-14 P 0AFC68C4871D6435D8AE6773914B3518CBCECFD3 770194AAF055F9EA87E64CA02E08FE540289067F 2018 2020-04-17 16:48:07Z CRAIG B THOMPSON MD 1275 York Avenue New York NY 10065 5558481260 true true 3475 X www.mskcc.org X LEADERSHIP IN THE PREVENTION, TREATMENT, AND CURE OF CANCER THROUGH EXCELLENCE, VISION , AND COST EFFECTIVENESS IN PATIENT CARE, OUTREACH PROGRAMS, RESEARCH, AND EDUCATION. 115 105 21014 960 -7985589 514762000 591441434 3683539000 4176082000 189791000 241751000 110965098 109215566 4499057098 5118490000 25459000 25208000 0 0 2319603271 2573375430 128216 0 69396458 1839463611 2060986681 4184654098 4659570111 314403000 458919889 10632552000 10620542000 4529742000 4194451000 6102810000 6426091000 X THE MISSION OF MEMORIAL SLOAN-KETTERING CANCER CENTER IS TO LEAD IN THE PREVENTION, DIAGNOSIS,TREATMENT AND CURE OF CANCER AND ASSOCIATED DISEASES THROUGH PROGRAMS OF EXCELLENCE IN RESEARCH, EDUCATION, OUTREACH AND COST-EFFECTIVE PATIENT CARE. LEADERSHIP IN PATIENT CARE: WE PLACE THE HIGHEST PRIORITY ON ADVANCING THE CARE OF CANCER PATIENTS THROUGH EARLY DETECTION, ACCURATE DIAGNOSIS, AND OPTIMAL TREATMENT. THESE THREE ELEMENTS LEAD TO THE MOST EFFECTIVE CANCER CARE POSSIBLE, WHICH IS ALSO THE MOST COST-EFFECTIVE CARE, WE STRIVE FOR EXCELLENCE IN ALL EXISTING AND EMERGING THERAPIES WITHOUT NEGLECTING THE NEED FOR ADVANCED APPROACHES IN PALLIATION. WE DELIVER THESE THERAPIES IN A CARING ENVIRONMENT THAT ENCOMPASSES PATIENTS AS WELL AS THEIR LOVED ONES. EXCELLENCE IN PATIENT CARE IS EXEMPLIFIED BY OUR MULTIDISCIPLINARY APPROACH, A CORE COMPETENCE OF OUR CENTER. WE ARE COMMITTED TO DEVELOPING OUTREACH PROGRAMS TO BRING EXCELLENCE IN CANCER CARE TO THE COMMUNITY. LEADERSHIP IN RESEARCH EXC false false 3646998499 2756000 3980533000 PATIENT CARE: MEMORIAL SLOAN-KETTERING CANCER CENTER EXPERTS HAVE ESTABLISHED STANDARDS OF CARE AND TREATMENT PROTOCOLS FOR EACH TYPE AND STAGE OF CANCER. OUR PHYSICIANS HAVE AN EXTRAORDINARY DEPTH AND BREADTH OF EXPERIENCE IN DIAGNOSING AND TREATING ALL FORMS OF THE DISEASE, FROM THE MOST COMMON TO THE VERY RARE. EACH YEAR, THEY TREAT MORE THAN 400 DIFFERENT SUBTYPES OF CANCER. THIS LEVEL OF SPECIALIZATION CAN HAVE AN OFTEN-DRAMATIC EFFECT ON A PATIENT'S CHANCES FOR A CURE OR CONTROL OF THEIR CANCER. WHILE WE ARE KNOWN FOR OUR ADVANCED, INNOVATIVE THERAPIES, OUR PHYSICIANS ARE EQUALLY WELL REGARDED FOR THEIR COMPASSION AND CONCERN. OUR DISEASE MANAGEMENT PROGRAM FEATURES 16 MULTIDISCIPLINARY CANCER TEAMS. PATIENTS ARE TREATED BY AS MANY DIFFERENT SPECIALISTS AS ARE NEEDED FOR THEIR PARTICULAR TYPE OF DISEASE, INCLUDING SURGEONS, MEDICAL ONCOLOGISTS, RADIATION ONCOLOGISTS, RADIOLOGISTS, PATHOLOGISTS, PSYCHIATRISTS, AND NURSES. OUR PATHOLOGISTS HAVE UNSURPASSED EXPERTISE IN USING ADVANCED METHODS TO ACCURATELY DIAGNOSE CANCER. BECAUSE OF THEIR SOLE FOCUS ON CANCER, OUR SURGEONS USE SURGICAL TECHNIQUES THAT PRESERVE FORM AND FUNCTION. OUR RADIATION ONCOLOGISTS ARE DEVELOPING AND PUTTING INTO CLINICAL PRACTICE LEADING-EDGE TECHNOLOGIES AND TECHNIQUES IN RADIATION THERAPY. IN ADDITION, THE CENTER OFFERS A FULL RANGE OF PROGRAMS TO HELP PATIENTS AND FAMILIES THROUGHOUT ALL PHASES OF TREATMENT, INCLUDING SUPPORT GROUPS, GENETIC COUNSELING, HELP MANAGING CANCER PAIN AND SYMPTOMS, REHABILITATION, INTEGRATIVE MEDICINE SERVICES, AND ASSISTANCE IN NAVIGATING LIFE AFTER TREATMENT. 643754336 21208000 195549000 RESEARCH: MEMORIAL SLOAN-KETTERING CANCER CENTER MAINTAINS ONE OF THE WORLD'S MOST DYNAMIC PROGRAMS OF CANCER RESEARCH. THE EXTRAORDINARY PATIENT CARE WE PROVIDE BENEFITS FROM OUR INNOVATIVE PROGRAMS IN BASIC, TRANSLATIONAL, AND CLINICAL RESEARCH. RESEARCH AT SLOAN-KETTERING INSTITUTE IS DEDICATED TO UNDERSTANDING THE BIOLOGY OF CANCER THROUGH PROGRAMS IN CELL BIOLOGY, GENETICS, BIOCHEMISTRY, MOLECULAR BIOLOGY, STRUCTURAL BIOLOGY, COMPUTATIONAL BIOLOGY, IMMUNOLOGY, AND THERAPEUTICS. INVESTIGATORS AT SLOAN-KETTERING INSTITUTE COLLABORATE WITH MEMORIAL HOSPITAL PHYSICIAN-SCIENTISTS, A PARTNERSHIP THAT HELPS SPEED IMPORTANT RESEARCH FINDINGS FROM THE LABORATORY TO THE BEDSIDE, IN A PROCESS KNOWN AS TRANSLATIONAL RESEARCH. MEMORIAL SLOAN-KETTERING CANCER CENTER ALSO ACTIVELY INITIATES AND PARTICIPATES IN CLINICAL TRIALS TO IDENTIFY MORE EFFECTIVE CANCER THERAPIES, AND OUR PHYSICIANS ARE CURRENTLY LEADING 1,072 CLINICAL TRIALS FOR PEDIATRIC AND ADULT CANCERS. THE HUMAN ONCOLOGY AND PATHOGENESIS PROGRAM (HOPP) IS A FURTHER EFFORT TO INCREASE INSTITUTIONAL RESEARCH STRENGTH IN AREAS IMPORTANT IN CONTEMPORARY TRANSLATIONAL RESEARCH. HOPP IS DESIGNED TO MELD EVEN MORE THOROUGHLY THE CULTURES OF BASIC BIOLOGIC SCIENCE AND CLINICAL ONCOLOGY, AUGMENTING THE WORK CONDUCTED IN THE LABORATORIES OF MEMORIAL SLOAN-KETTERING CANCER CENTER'S PHYSICIAN-SCIENTISTS. 244844698 1244000 EDUCATION: EDUCATION IS A VITAL PART OF MEMORIAL SLOAN-KETTERING CANCER CENTER'S MISSION. OUR TRAINING PROGRAMS PREPARE PHYSICIANS AND SCIENTISTS FOR CAREERS IN THE BIOMEDICAL SCIENCES. OUR COLLABORATIONS WITH THE ROCKEFELLER UNIVERSITY, CORNELL UNIVERSITY, AND WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY OFFER PHD PROGRAMS IN CHEMICAL BIOLOGY, COMPUTATIONAL BIOLOGY AND MEDICINE, AND THE MEDICAL SCIENCES. THE CENTER ALSO PARTNERS WITH WEILL MEDICAL COLLEGE AND THE ROCKEFELLER UNIVERSITY TO OFFER A MD/PHD DEGREE FOR ASPIRING PHYSICIAN-SCIENTISTS. THE CENTER HAS A PHD PROGRAM IN CANCER BIOLOGY THROUGH ITS LOUIS V. GERSTNER, JR. GRADUATE SCHOOL OF BIOMEDICAL SCIENCES. THIS NOVEL PROGRAM, HAS BEEN ENROLLING STUDENTS SINCE 2006, TRAINS BASIC LABORATORY SCIENTISTS TO WORK IN RESEARCH AREAS DIRECTLY RELEVANT TO CANCER AND OTHER HUMAN DISEASES. WE ALSO OFFER POSTGRADUATE CLINICAL FELLOWSHIPS TO TRAIN PHYSICIANS WHO SEEK SPECIAL EXPERTISE IN A PARTICULAR TYPE OF CANCER AND POSTGRADUATE RESEARCH FELLOWSHIPS THAT PROVIDE PHYSICIANS AND SCIENTISTS WITH ADVANCED LABORATORY RESEARCH TRAINING. WITH FACULTY APPOINTMENTS AT THE WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY, OUR CLINICAL STAFF ALSO TRAIN RESIDENTS AND MEDICAL STUDENTS. 4535597533 true true false true false false false false false true true true false false true false false true true true true false false false true false true true true true true true false false false false false false false true true true true false false false true true true true false false true X 1491 0 true 21014 true true true false false false false true true false false false false true false X 115 105 true false false false true true false true true false false true true true true true true true true true true AK AZ AR FL GA IL KS LA MD MA MI MN MS MO NV NH NJ NM NY ND OH OK PA RI SC TN TX UT WA WI X X MARK K SVENNINGSON 6462273414 633 3RD AVENUE NEW YORK NY 10017 X RICHARD I BEATTIE SEE SCHEDULE O 3.0 0.0 X 0 0 0 IAN COOK SEE SCHEDULE O 3.0 0.0 X 0 0 0 STANLEY F DRUCKENMILLER SEE SCHEDULE O 10.0 0.0 X 0 0 0 ANTHONY B EVNIN SEE SCHEDULE O 10.0 0.0 X 0 0 0 ROGER W FERGUSON SEE SCHEDULE O 3.0 0.0 X 0 0 0 WILLIAM E FORD SEE SCHEDULE O 3.0 0.0 X 0 0 0 RICHARD N FOSTER SEE SCHEDULE O 3.0 0.0 X 0 0 0 STEPHEN FRIEDMAN SEE SCHEDULE O 3.0 0.0 X 0 0 0 ELLEN V FUTTER SEE SCHEDULE O 3.0 0.0 X 0 0 0 LOUIS V GERSTNER JR SEE SCHEDULE O 3.0 0.0 X 0 0 0 JONATHAN N GRAYER SEE SCHEDULE O 3.0 0.0 X 0 0 0 JAMIE GREGORY SEE SCHEDULE O 3.0 0.0 X 0 0 0 BENJAMIN W HEINEMAN JR SEE SCHEDULE O 3.0 0.0 X 0 0 0 JEFFREY P JOHNSON SEE SCHEDULE O 3.0 0.0 X 0 0 0 DAVID H KOCH SEE SCHEDULE O 3.0 0.0 X 0 0 0 MARIE-JOSEE KRAVIS SEE SCHEDULE O 3.0 0.0 X 0 0 0 JAMIE C NICHOLLS SEE SCHEDULE O 3.0 0.0 X 0 0 0 JAMES G NIVEN SEE SCHEDULE O 3.0 0.0 X 0 0 0 BRUCE C RATNER SEE SCHEDULE O 3.0 0.0 X 0 0 0 ALEXANDER T ROBERTSON SEE SCHEDULE O 3.0 0.0 X 0 0 0 JAMES D ROBINSON III SEE SCHEDULE O 3.0 0.0 X 0 0 0 VIRGINIA M ROMETTY SEE SCHEDULE O 3.0 0.0 X 0 0 0 STEPHEN C SHERRILL SEE SCHEDULE O 3.0 0.0 X 0 0 0 LAVINIA BRANCA SNYDER SEE SCHEDULE O 3.0 0.0 X 0 0 0 PETER J SOLOMON SEE SCHEDULE O 3.0 0.0 X 0 0 0 JOHN R STRANGFELD SEE SCHEDULE O 10.0 0.0 X 0 0 0 SCOTT M STUART SEE SCHEDULE O 10.0 0.0 X 0 0 0 PETER A WEINBERG SEE SCHEDULE O 10.0 0.0 X 0 0 0 DEBORAH C WRIGHT SEE SCHEDULE O 3.0 0.0 X 0 0 0 CLIFTON S ROBBINS SEE SCHEDULE O 10.0 0.0 X X 0 0 0 NORMAN C SELBY SEE SCHEDULE O 10.0 0.0 X X 0 0 0 DOUGLAS WARNER III SEE SCHEDULE O 10.0 0.0 X X 0 0 0 JOSE BASELGA MD PHD PIC-CHIEF MED OFF. TO 9/13/18 50.0 0.0 X X 1649335 0 83300 MICHAEL P GUTNICK EXECUTIVE VP & CFO 50.0 0.0 X X 1059967 0 70267 KATHRYN MARTIN CHIEF OPERATING OFFICER 50.0 0.0 X X 1375127 0 586105 MARK SVENNINGSON SVP FINANCE 50.0 0.0 X X 679765 0 76620 CRAIG B THOMPSON MD PRESIDENT & CEO 50.0 0.0 X X 2185786 0 1240566 KERRY BESSEY SVP & CHIEF HR OFFICER 50.0 0.0 X 718302 0 75910 ERIC M COTTINGTON PHD SVP RESEARCH & TECHNOLOGY MGMT 50.0 0.0 X 678172 0 77530 FREDRICK GROVES EVP & HOSPITAL ADMINISTRATOR 50.0 0.0 X 644193 0 55037 JASON KLEIN SVP-CHIEF INVESTMENT OFFICER 50.0 0.0 X 1583444 0 1018320 CAROLYN B LEVINE ESQ DEPUTY GEN COUNSEL CORP SECTY 50.0 0.0 X 406458 0 60467 JORGE LOPEZ ESQ EVP GENERAL COUNSEL 50.0 0.0 X 963244 0 73767 EDWARD MAHONEY SVP FACILITIES MGMT & CONST 50.0 0.0 X 751074 0 70639 AVICE MEEHAN SVP CH COMMUNICATION OFFICER 50.0 0.0 X 445845 0 61396 RICHARD K NAUM SVP DEVELOPMENT RETIRED 7/1/18 50.0 0.0 X 229155 0 11899 PATRICIA C SKARULIS SVP-CHIEF INFORMATION OFFICER 50.0 0.0 X 705910 0 55934 DEBRA BERNS ESQ SVP & CHIEF RISK OFICER 50.0 0.0 X 514225 0 38436 KENNETH MANOTTI SVP DEVELOPMENT 50.0 0.0 X 570442 0 51462 JOAN MASSAGUE PhD DIRECTOR SLOAN-KETTERING INST. 50.0 0.0 X 1103781 0 60988 MARK BILSKY MD ATTENDING-DEPT OF NEUROSURGERY 50.0 0.0 X 1709434 0 72426 JOSEPH DISA MD ATTENDING PLASTIC SURGERY 50.0 0.0 X 1669516 0 78325 MARIO LEITAO MD ATTENDING SURGERY 50.0 0.0 X 1539849 0 68615 JEFFREY DREBIN MD CHAIRMAN ATTENDING-SURGERY 50.0 0.0 X 2458037 0 72110 BABAK MEHRARA MD CHIEF ATTENDING-SURGERY 50.0 0.0 X 1863632 0 68631 EDWIN TALIAFERRO VP INTERNAL AUDIT & COMPLIANCE 0.0 0.0 X 121539 0 9635 25626232 0 4138385 6463 true true false TURNER CONSTRUCTION 375 HUDSON STREET NEW YORK NY 10014 GENERAL CONSTRUCTION 259211227 HUNTER ROBERTS CONSTRUCTION GR LLC 2 WORLD FINANCIAL CENTER NEW YORK NY 10001 GENERAL CONSTRUCTION 75715154 JGN CONSTRUCTION CORP 66-40 69TH STREET MIDDLE VILLAGE NY 11379 GENERAL CONSTRUCTION 19253167 LEND LEASE US CONSTRUCTION 200 PARK AVENUE NEW YORK NY 10166 GENERAL CONSTRUCTION 16718877 FIDELUS TECHNOLOGIES 240 W 35TH STREET NEW YORK NY 10001 IT CONSULTANTS 9449691 233 3832434 199057000 388552000 7865351 591441434 MEDICAL CARE 622310 3980533000 3980533000 NON-GOVERNMENT SPONSORED RESEARCH 541711 195549000 195549000 4176082000 67288000 -7881828 75169828 2166000 2166000 75679000 75679000 38021000 45154000 -7133000 0 -7133000 -7133000 566010260 393713260 172297000 172297000 172297000 945536 3832434 1124000 -178464 -178464 0 0 0 0 0 0 CAFETERIA 722212 7376000 7376000 VENDOR DISCOUNTS 561439 975000 975000 SERVICES PROVIDED 561439 4987000 4987000 27510030 -103761 27613791 40848030 5118490000 4176082000 -7985589 358952155 1000000 1000000 24208000 24208000 0 0 20032870 15668644 3413876 950350 457950 447128 10822 2008321518 1973873326 9709627 24738565 160171407 156781842 1604251 1785314 264426449 258617755 945364 4863330 119965236 117423626 1202922 1338688 0 13263144 12410120 687071 165953 1232679 978785 252627 1267 872735 872735 0 5835331 5835331 79612182 68781274 1764906 9066002 28439351 23893891 71336 4474124 276013456 254106615 5311424 16595417 50050933 48948270 361391 741272 1834895 1834895 121971838 107916232 13837096 218510 13450398 12763324 209368 477706 0 14095888 12889721 548635 657532 47044528 41402593 5641935 0 300239282 293351232 5670755 1217295 15790159 15474573 183571 132015 PHARMACEUTICALS 904359502 904359502 MEDICAL/SURGICAL SUPPLIES 242728584 242728584 PROVISION BAD DEBT-REG ASSMT 12210237 12210237 UBIT EXPENSE 219559 219559 -68278000 -65510476 -4740642 1973118 4659570111 4535597533 54576120 69396458 X 15357988 7058594 8299394 9695000 7574000 1130188000 758689000 587401000 549698000 442263000 557956000 0 0 0 0 36387000 38362000 73204000 64303000 118020000 117714000 7474813000 3190475000 3855532000 4284338000 3502211000 3464900000 856740000 756852000 20911000 20156000 0 0 0 0 10632552000 10620542000 876391000 993300000 0 0 0 0 1439048000 1051371000 0 0 0 0 0 0 1350000000 1350000000 864303000 799780000 4529742000 4194451000 X 4628681000 5028329000 798880000 695455000 675249000 702307000 6102810000 6426091000 10632552000 10620542000 X 458919889 -189477000 53838111 X false true X true true true X 4 SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH 131624182 4 true 0 0 MEMORIAL HOSPITAL FOR CANCER & ALLIED DISEASES 131624082 3 true 0 0 MEMORIAL SLOAN-KETTERING CANCER CENTER 131924236 3 true 0 0 LOUIS V GERSTNER JR GRADUATE SCHOOL OF BIOMEDICAL SCIENCES 202212588 2 true 0 0 4 0 0 544924247 437479585 484699242 514556000 591422434 2573081508 0 0 544924247 437479585 484699242 514556000 591422434 2573081508 43292614 2529788894 210605148 245714279 201917796 100111000 190676000 949024223 0 0 3522105731 16726283987 0.71826 0.70347 X true false false false false 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 SUPPORTED ORGANIZATIONS SUPPORT FROM THE SUPPORTING ORGANIZATIONS RELATE PRINCIPALLY TO THE SHARING OF CERTAIN FACILITIES, EQUIPMENT, PERSONNEL COSTS, EDUCATION, INSURANCE AND ALLOCATIONS. AMOUNTS DUE TO OR DUE FROM AFFILIATES RESULTING FROM THESE SERVICES DO NOT BEAR INTEREST. SUPPORTING ORGANIZATIONS NAME OF SUPPORTING ORGANIZATION EIN TYPE S.K.I. REALTY 13-3389586 12a MSK INSURANCE US 83-0363317 12a MSKCC PROTON INC. 35-2397819 12a MSKCC PROPERTIES, LLC. 35-2464610 12a RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false true false false false false true 577094 false true 295641 872735 false LOBBYING COSTS MSKCC ENGAGES IN FEDERAL, STATE, AND LOCAL LOBBYING. THE CENTERS FEDERAL LOBBYING EFFORT FOCUSES ON PATIENT CARE AND REIMBURSEMENT ISSUES. PATIENT CARE ADVOCACY INCLUDES ENSURING PATIENTS ARE ABLE TO ACCESS CLINICAL TRIALS AND CANCER HOSPITALS ARE ABLE TO EFFECTIVELY RESEARCH POTENTIAL TREATMENTS FOR CANCER AS WELL AS PREVENTATIVE AND PALLIATIVE MEASURES. THE CENTER ALSO SEEKS EQUITABLE REIMBURSEMENT FOR SERVICES RENDERED TO PATIENTS ENROLLED IN ENTITLEMENT PROGRAMS. FROM TIME TO TIME, THE CENTER WEIGHS IN ON OTHER FEDERAL LEGISLATION THAT IMPACTS CANCER CARE AND HOSPITALS IN GENERAL. THE CENTERS STATE LOBBYING EFFORTS FOCUS ON ISSUES RELATING TO PATIENT CARE, PUBLIC HEALTH, AND HOSPITAL OPERATIONS. PATIENT CARE AND PUBLIC HEALTH ISSUES MAY INCLUDE ACCESS TO CARE AND CANCER PREVENTION AND SCREENING, INCLUDING AS PART OF STATE BUDGET LEGISLATION. OUR ADVOCACY ON HOSPITAL OPERATIONS CENTERS ON ISSUES RELATING TO PROFESSIONAL LICENSURE AND CONTINUING EDUCATION, SCOPE OF PRACTICE, HOSPITAL STAFFING, AND HEALTH AND SAFETY REQUIREMENTS. ON OCCASION, THE CENTER ENGAGES IN LOCAL LOBBYING ON ISSUES RANGING FROM BUILDING ORDINANCES TO RADIATION CONTROL. THE CENTER ALSO INCURS COSTS FOR FEDERAL, STATE, AND LOCAL LOBBYING BY ASSOCIATIONS AND OTHER ORGANIZATIONS OF WHICH IT IS A MEMBER. PART II-B LINE 1(I) OTHER ACTIVIES LOBBYING PORTION OF DUES PAID IN 2018 GREATER NEW YORK HOSPITAL ASSOCIATION $ 253,885 AMERICAN HOSPITAL ASSOCIATION 31,257 NYSSA 8,120 AMERICAN COLLEGE OF SURGEONS 1,020 OTHERS 1,359 TOTAL $ 295,641 false false 869056000 152114000 101997000 1123167000 802748000 52800000 13508000 869056000 778565000 18986000 5197000 802748000 772740000 17561000 -2097000 9639000 778565000 753249000 25760000 9616000 15885000 772740000 0.37500 0.62500 true true false 380703000 380703000 5256264000 1825208000 3431056000 117699000 75197000 42502000 1720147000 1290070000 430077000 4284338000 PRIVATE EQUITY & VENTURE CAP. 756852000 F 756852000 0 PENSION AND POSTRETIREMENT 390984000 INSURANCE RESERVES 279617000 DEFERRED COMPENSATION 65895000 ASSET RETIREMENT OBLIGATIONS 38868000 DEFERRED GIFT ANNUITY 17268000 OTHER LIABILITIES 7148000 799780000 4961027000 -189477000 46278000 -143199000 5104226000 14264000 14264000 5118490000 4690584111 46278000 46278000 4644306111 14264000 1000000 15264000 4659570111 USE OF ENDOWMENT FUNDS PERMANENT ENDOWMENT FUNDS ARE HELD BY THE ORGANIZATION IN PERPETUITY. INCOME EARNED ON THE FUND BALANCE IS USED TO SUPPORT THE OPERATIONS OF MEMORIAL SLOAN-KETTERING CANCER CENTER AND ITS AFFILIATED ORGANIZATIONS PART XI LINE 2D REVENUE RENTAL EXPENSES OFFSETS REVENUE $45,154,000 FUNDRAISING COSTS OFFSETS REVENUE 1,124,000 TOTAL $46,278,000 PART XII LINE 2D EXPENSES RENTAL EXPENSES OFFSETS REVENUE $45,124,000 FUNDRAISING COSTS OFFSETS REVENUE 1,124,000 TOTAL $46,278,000 PART XII LINE 4B PAYMENT OF A GRANT TO THE RALPH LAUREN CENTER FOR $1,000,000 RECORDED AS NON-OPERATING EXPENSE. FIN 48 LIABILITY FOR UNCERTAIN TAX POSITIONS A FIN 48 FOOTNOTE DISCLOSURE, RELATING TO THE ACCOUNTING FOR INCOME TAXES, WAS NOT REQUIRED BECAUSE THERE WAS NO MATERIAL IMPACT ON THE INSTITUTION'S FINANCIAL STATEMENTS. true true true true true true true false false false false false false false false false false true NONDISCRIMINATORY POLICY THE SCHOOL'S NONDISCRIMINATORY POLICY IS PUBLICIZED ON ITS WEB SITE: HTTP://WWW.SLOANKETTERING.EDU/GERSTNER/HTML/54499.CFM. ALL APPLICANTS TO THE LOUIS V. GERSTNER JR., GRADUATE SCHOOL OF BIOMEDICAL SCIENCES ARE CONSIDERED ON THE BASIS OF MERIT. THE SCHOOL DOES NOT DISCRIMINATE ON THE BASIS OF GENDER, RACE, COLOR, CREED, RELIGION, AGE, NATIONAL ORIGIN, DISABILITY, VETERAN STATUS, MARITAL STATUS, SEXUAL ORIENTATION, OR CITIZENSHIP STATUS IN ACCORDANCE WITH INSTITUTIONAL POLICY AND IN COMPLIANCE WITH THE REQUIREMENTS OF THE CIVIL RIGHTS ACT, THE EDUCATION ADMENDMENTS, THE REHABILITATION ACT, THE AGE DISCRIMINATION ACT, AND THE AMERICANS WITH DISABILITIES ACT. EXCISE TAX ON NET INVESTMENT INCOME THE LOUIS V GERSTNER JR, GRADUATE SCHOOL OF BIOMEDICAL SCIENCES DOES NOT MEET THE CRITERIA OF SECTION 4968 AND, THEREFORE, IS NOT SUBJECT TO THE EXCISE TAX ON NET INVESTMENT INCOME. East Asia and the Pacific Program Services PATIENT CARE CONF 402135 East Asia and the Pacific Program Services INVESTMENT MEETINGS 73168 East Asia and the Pacific Program Services RESEARCH CONFERENCES 62720 Central America and the Caribbean Program Services PATIENT CARE CONF 38240 Central America and the Caribbean Program Services RESEARCH CONFERENCES 2709 Central America and the Caribbean Program Services INVESTMENT MEETINGS 772 Europe (Including Iceland and Greenland) Program Services PATIENT CARE CONF 990907 Europe (Including Iceland and Greenland) Program Services RESEARCH CONFERENCES 209673 Europe (Including Iceland and Greenland) Program Services INVESTMENT MEETINGS 71879 Middle East and North Africa Program Services PATIENT CARE CONF 130271 Middle East and North Africa Program Services RESEARCH CONFERENCES 68408 Middle East and North Africa Program Services INVESTMENT MEETINGS 1093 North America Program Services PATIENT CARE CONF 154026 North America Program Services RESEARCH CONFERENCES 23130 North America Program Services INVESTMENT MEETINGS 17294 Russia and the Newly Independent States Program Services PATIENT CARE CONF 974 South America Program Services PATIENT CARE CONF 30754 South America Program Services RESEARCH CONFERENCES 1141 South Asia Program Services PATIENT CARE CONF 69078 South Asia Program Services RESEARCH CONFERENCES 13265 South Asia Program Services INVESTMENT MEETINGS 23426 Sub-Saharan Africa Program Services PATIENT CARE CONF 65000 Central America and the Caribbean Investments 1650067000 Europe (Including Iceland and Greenland) Investments 40944000 Sub-Saharan Africa Investments 8272000 Europe (Including Iceland and Greenland) 0 1 Program Services Bioinformatics 191551 East Asia and the Pacific 0 1 Program Services Bioinformatics 163820 0 2 0 2 2278153 1699810281 1702088434 true false true true true true ORGANIZATION'S PROCEDURES FOR THE USE OF FUNDS OUTSIDE THE US MEMORIAL SLOAN-KETTERING CANCER CENTER DOES NOT MAKE GRANTS OR USE GRANT MONEY OUTSIDE OF THE UNITED STATES. INVESTMENTS BY REGION VALUES SHOWN IN COLUMN F ARE THE MARKET VALUES FOR THE INVESTMENTS AT DECEMBER 31. AL AK AZ AR CA CO CT DE DC FL GA GU HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA PR RI SC SD TN TX VI UT VT VA WA WV WI WY SPRING BALL 1418937 980224 438713 0 110486 10539 122442 SPECIAL PROJ. 914800 872680 42120 73718 28639 5 2444233 1979530 464703 405123 50737 66650 255666 4777970 3832434 945536 478841 161223 77189 406747 1124000 -178464 true true X true X 500. true X 500. true true false true true 19311575 1388094 17923481 0.00380 243362496 62500486 180862010 0.03880 262674071 63888580 198785491 0.04260 16423287 16423287 0.00350 244844699 44487567 200357132 0.04300 3139730 3139730 0.00070 529690023 337014552 192675471 0.04140 1160760 1160760 0.00020 795258499 381502119 413756380 0.08880 1057932570 445390699 612541871 0.13140 828 828 33529 33529 296190 296190 371229 371229 181511 35000 146511 0.00020 883287 35000 848287 0.00020 false 55139234 6859172 1066027933 1375251079 -309223146 X true true 1 1 MEMORIAL HOSP FOR CANCER & ALLIED DIS 1275 YORK AVENUE NEW YORK NY 10065 www.mskcc.org 7002020H X X X X Urgent Care Center SEE PART V OF SCH H MEMORIAL HOSP FOR CANCER & ALLIED DIS 1 false false true X X X X X X X X X X 16 true false false true X www.mskcc.org/communityserviceplans X X true 16 true www.mskcc.org/communityserviceplans false true X 500. 500. X X X X X true true X X X X true X SEE SCH H, PART V, SECTION C X www.mskcc.org/financial-assistance X SEE SCH H, PART V, SECTION C X X X X X X true X false X X X X true X false false PART V FACILITY INFORMATION SECTION C. SUPPLEMENTAL INFORMATION FOR PART V, SECTION B. LINE 3J MSK CONDUCTED A COMMUNITY HEALTH NEEDS ASSESSMENT IN THE FALL OF 2016 TO DETERMINE THE CRITICAL CANCER-RELATED HEALTH CONCERNS FACING RESIDENTS IN OUR 23-COUNTY CATCHMENT AREA IN NEW YORK, NEW JERSEY, AND CONNECTICUT. WE ANALYZED CANCER STATISTICS ON INCIDENCE, PREVALENCE, AND MORTALITY. WE ALSO REVIEWED KEY HEALTH TRENDS AMONG CANCER PATIENTS, MULTICULTURAL POPULATIONS, AND THE PUBLIC. LINE 5 TO ENGAGE THE BROAD COMMUNITY IN OUR HEALTH NEEDS ASSESSMENT, MSK HELD A SERIES OF COMMUNITY FORUMS IN HARLEM, BROOKLYN, AND MANHATTAN, AS WELL AS WEBINARS WITH FURTHER REACHES TO OUR CATCHMENT AREAS IN LONG ISLAND, WESTCHESTER AND NEW JERSEY. THESE FORUMS WERE CONDUCTED TO CONNECT WITH REPRESENTATIVES FROM COMMUNITY-BASED ORGANIZATIONS INCLUDING PRIVATE, NON-PROFIT, PUBLIC, AND GOVERNMENT AGENCIES THAT WORK TO MEET COMMUNITY NEEDS WITH SERVICES AND RESOURCES THROUGHOUT NEW YORK CITY AND ITS SURROUNDING COMMUNITIES. REPRESENTATIVES FROM 22 COMMUNITY-BASED ORGANIZATIONS PARTICIPATED IN THE FORUMS AND SERVE A DIVERSE RANGE OF CLIENTS. SERVICES PROVIDED BY THESE ORGANIZATIONS INCLUDE CANCER SUPPORT SERVICES, DOMESTIC VIOLENCE SUPPORT, IMMIGRATION ASSISTANCE, AND PRIMARY CARE SERVICES. COMMUNITY ORGANIZATIONS THAT PROVIDED INPUT ON MSK'S HEALTH NEEDS ASSESSMENT INCLUDE: AMERICAN CANCER SOCIETY - LONG ISLAND CHAPTER AMERICAN CANCER SOCIETY - NEW YORK CITY CHAPTER ARAB AMERICAN FAMILY SUPPORT CENTER BRONX HEALTH REACH BROOKLYN COMMUNITY SERVICES CANCER AND CAREERS CANCER CARE COALICION MEXICANA COMMUNITY ACTION NETWORK - HEALTHY START BROOKLYN FRIENDS OF KAREN GILDA'S CLUB HARLEM UNITED HISPANIC FEDERATION MAKE THE ROAD NEW YORK MEXICAN CONSULATE NATIONAL OVARIAN CANCER COALITION NEW YORK CITY DEPARTMENT OF HEALTH & MENTAL HYGIENE NEW YORK CITY FAMILY JUSTICE CENTER SHARE THE CREATIVE CENTER THE LEUKEMIA & LYMPHOMA SOCIETY QUEENS LIBRARY LINE 7D SUMMARY FINDINGS OF MSK'S CHNA WERE SENT TO COMMUNITY-BASED ORGANIZATIONS WITH WHOM WE WORK AND WERE ALSO INCORPORATED INTO OUR ANNUAL COMMUNITY SERVICE PLAN (CSP) TO ADDRESS THE IDENTIFIED HEALTH NEEDS. THE CSP WAS DISTRIBUTED TO LOCAL ELECTED OFFICIALS AND OTHER COMMUNITY ORGANIZATIONS. THE CHNA WAS ALSO PUBLISHED TO OUR WEBSITE AT WWW.MSKCC.ORG/COMMUNITYSERVICEPLANS, FOR PUBLIC CONSUMPTION. WE PUBLISHED THE CHNA IN 2016 WHEN THE ASSESSMENT WAS COMPLETED. WE ARE CURRENTLY CONDUCTING THE NEXT CYCLE WHICH IS DUE BY DECEMBER 31, 2019. LINE 11 THE CHNA FOUND THAT MSK IS CURRENTLY ADDRESSING MANY AREAS OF NEED INCLUDING COLLABORATIVE INITIATIVES, FINANCIAL INFORMATION/ASSISTANCE, PREVENTION PROGRAMS, TRANSPORTATION AND PATIENT NAVIGATION. IN ADDITION, MSK HAS IDENTIFIED SOME NEW AREAS OF FOCUS BECAUSE OF THE CHNA. THESE INCLUDE KNOWLEDGE GATHERING AND NEW PROGRAMMING TO REACH MULTICULTURAL POPULATIONS SPECIFICALLY TARGETED TO THE HISPANIC POPULATION IN OUR SERVICE AREA; ENHANCED COLLABORATIONS WITH COMMUNITY-BASED ASSOCIATIONS; FINANCIAL ASSISTANCE AWARENESS; CANCER SCREENING AMONG UNDERSERVED POPULATIONS; INCREASE PARTICIPATION IN MSK'S SMOKING CESSATION SERVICES; AND EDUCATIONAL MATERIALS FOR MULTICULTURAL AUDIENCES IN SPANISH AND RUSSIAN. ADDITIONAL INFORMATION ON IDENTIFIED NEEDS AND WHAT NEEDS ARE NOT BEING ADDRESSED TOGETHER WITH THE REASON WHY SUCH NEEDS ARE NOT BEING ADDRESSED CAN BE FOUND IN THE HOSPITAL'S MOST RECENT COMPREHENSIVE THREE-YEAR CSP AND CHNA REPORT POSTED AT WWW.MSKCC.ORG/COMMUNITYSERVICEPLANS. IDENTIFIED NEEDS THAT MSK CANNOT ADDRESS ADEQUATELY BECAUSE THEY ARE BEYOND OUR SCOPE OF SERVICE ARE LEGAL ADVOCACY, POLITICAL ADVOCACY, AND SUPPORT SERVICES FOR CRISIS INTERVENTION. WITHIN THESE CONSTRAINTS, MSK PROVIDES REFERRALS TO EXTERNAL ORGANIZATIONS THAT RESPOND TO THESE NEEDS. LINE 13G NEW PATIENTS WHO RESIDE IN NEW YORK OR NEW JERSEY MAY QUALIFY FOR FINANCIAL ASSISTANCE. EXISTING PATIENTS MAY QUALIFY FOR AID REGARDLESS OF WHERE THEY LIVE IN THE UNITED STATES. LINE 15E FOR MANY YEARS MSK HAS PROVIDED FINANCIAL HELP TO PATIENTS IN NEED. OUR FINANCIAL ASSISTANCE PROGRAM (FAP) AIDS UNINSURED AND UNDERINSURED PATIENTS WITH HOUSEHOLD INCOME UP TO FIVE TIMES THE FEDERAL POVERTY LEVEL (FPL) WHO CANNOT GET PUBLICLY FUNDED HEALTH INSURANCE OR CANNOT AFFORD TO PAY FOR THEIR MEDICAL CARE. TO BE CONSIDERED FOR THE FAP, PATIENTS ARE ASKED TO PROVIDE CERTAIN PERTINENT DOCUMENTATION TO ASSIST IN DETERMINING THEIR ELIGIBILITY AND THE AMOUNT OF FINANCIAL ASSISTANCE THEY ARE QUALIFIED TO RECEIVE. TO FURTHER ENHANCE THE PROCESS, WE STRATEGICALLY PLACE FINANCIAL ASSISTANCE BROCHURES AT EACH REGISTRATION SITE AND AT THE FRONT DESK OF PATIENT FINANCIAL SERVICES OFFICE. WE INCLUDE COPIES OF THE FAP BROCHURE WITH THE INITIAL HOSPITAL BILL TO EVERY NEW PATIENT. MENTION OF THE FAP IS ALSO MADE IN EVERY PATIENT STATEMENT AND LETTER SENT TO THEM. REFERENCE IS MADE IN THE COLLECTION LETTERS FROM COLLECTION AGENCIES AS WELL. FURTHERMORE, THE FINANCIAL ASSISTANCE INFORMATION IS POSTED ON THE MSK WEBSITE AT WWW.MSKCC.ORG/FINANCIAL-ASSISTANCE. LINE 16 THE PLAIN LANGUAGE SUMMARY AND APPLICATION ARE AVAILABLE ON OUR WEBSITE AT: WWW.MSKCC.ORG/FINANCIAL-ASSISTANCE. A PATIENT CAN ALSO REQUEST A COPY BY CALLING OUR DEDICATED FINANCIAL ASSISTANCE LINE AT 212-639-3810. LINE 20D REGARDING "PRESUMPTIVE ELIGIBILITY", HOSPITALS QUALIFY PATIENTS FOR CHARITY CARE AS PART OF THE BENEFIT THEY PROVIDE TO THE SURROUNDING COMMUNITIES. BY USING TECHNOLOGY THAT LEVERAGES CREDIT-SCORE-LIKE DATA, DEMOGRAPHIC INFORMATION AND SOCIAL MEDIA DATA, THEY DETERMINE WHETHER PATIENTS ARE LIKELY TO QUALIFY FOR CHARITY CARE. CURRENTLY, WE ARE NOT USING THIS TECHNOLOGY AT MSK, HOWEVER, WE DO SOMETIMES CONDUCT PRELIMINARY FINANCIAL SCREENINGS VIA TELEPHONE TO ASCERTAIN ELIGIBILITY FOR OUR FINANCIAL ASSISTANCE PROGRAM. ONCE THE PATIENT PROVIDES THE REQUIRED DOCUMENTS THE CASE IS FINALIZED. LINE 20E NEITHER MSK NOR ITS COLLECTION AGENCIES PURSUE ANY EXTRAORDINARY COLLECTION ACTIONS AGAINST ITS PATIENTS. PRIOR TO REFERRING A PATIENT'S ACCOUNT TO A COLLECTION AGENCY MSK SENDS THE FAP BROCHURE WITH THE INITIAL HOSPITAL BILL TO EVERY NEW PATIENT TO MAKE THEM AWARE OF THE CHARITY CARE/FINANCIAL ASSISTANCE PROGRAM. THE FAP IS MENTIONED IN EVERY PATIENT STATEMENT AND LETTER THAT IS SENT TO A PATIENT. THE FAP IS ALSO MENTIONED IN EVERY COLLECTION LETTER SENT TO PATIENTS BY THE COLLECTION AGENCIES. EVEN AFTER A PATIENT'S ACCOUNT IS SENT TO COLLECTIONS, SHE/HE CAN STILL APPLY FOR FINANCIAL ASSISTANCE. IT IS NEVER TOO LATE TO APPLY FOR THE FINANCIAL ASSISTANCE AND IF ELIGIBLE, RETROACTIVE FAP COVERAGE WOULD BE PROVIDED TO THE PATIENT. LINE 21 ALL MSK'S PATIENTS REQUIRING URGENT CARE ARE PROVIDED WITH THE SERVICE AT OUR URGENT CARE CENTER REGARDLESS OF THEIR INSURANCE AND/OR FINANCIAL LIMITATION. FURTHERMORE, SERVICES ARE PROVIDED EVEN IF A DETERMINATION REGARDING ELIGIBILITY FOR MSK'S FAP HAS NOT YET BEEN MADE. The Memorial Hospital Urgent Care Center (UCC), open seven days a week, 24 hours a day, is staffed at all times with an attending physician. The primary purpose of the UCC is to treat registered Memorial Hospital patients who are acutely ill. The UCC also treats visitors who become acutely ill on the premises and cannot be transferred to New York Presbyterian/Weill Cornell Medical Center, visitors who are injured on the premises and employees who become ill on duty after Employee Health Service hours. Except as indicated above, the UCC does not treat unregistered individuals who present for treatment, but will manage their presentations. The UCC complies with the Emergency Treatment and Active Labor Act of 1996 (42 USC Sec. 1395dd). 5 MSK BASKING RIDGE 136 MOUNTAIN VIEW BLVD BASKING RIDGE NJ 07920 EXTENSION CLINIC MSK MONMOUTH 480 RED HILL ROAD MIDDLE TOWN NJ 07748 EXTENSION CLINIC MSK BERGEN 225 SUMMIT AVENUE MONTVALE NJ 07901 EXTENSION CLINIC BENDHEIM CENTER FOR INTEGRATIVE MEDICINE 1429 FIRST AVENUE NEW YORK NY 10021 EXTENSION CLINIC MSK CLINICAL GENETICS SERVICE 222 EAST 70TH STREET NEW YORK NY 10021 EXTENSION CLINIC SCHEDULE H, PART VI PART 1, LINE 3A A PATIENT WITH INCOME LESS THAN OR EQUAL TO 500% OF THE FEDERAL POVERTY GUIDELINES (FPG) IS ELIGIBLE FOR THE INSTITUTION'S FINANCIAL ASSISTANCE PROGRAM (FAP). THE INSTITUTION MAY REDUCE THE FEES INCURRED BY THE PATIENT OR ACCEPT AS FULL PAYMENT AMOUNTS PAID BY THE INSURANCE CARRIER ON THE PATIENT'S BEHALF. IN ADDITION, A PATIENT MAY ALSO QUALIFY FOR ASSISTANCE EVEN IF HIS/HER INCOME IS GREATER THAN THE THRESHOLD LIMIT. THE INSTITUTION ADJUSTS PATIENTS' INCOME FOR ROUTINE MONTHLY EXPENSES, INCLUDING TAXES, TO DETERMINE "DISPOSABLE INCOME". MSK ALSO DEDUCTS A SPECIFIC AMOUNT (DEBT BURDEN) AS A MONTHLY CLOTHES AND FOOD ALLOWANCE BASED ON A PATIENT'S FAMILY SIZE IN EVALUATING THE TYPE AND AMOUNT OF ASSISTANCE NEEDED. THE TABLE BELOW ILLUSTRATES THE INCOME GUIDELINE USED IN EVALUATING THE PATIENT'S FINANCIAL STATUS. BELOW ILLUSTRATES THE INCOME GUIDELINE USED IN EVALUATING THE PATIENT'S FINANCIAL STATUS. FAMILY SIZE ALLOWED INCOME RESOURCE LEVELS 1 $ 60,700 $ 37,875 2 $ 82,300 $ 55,500 3 $ 103,900 $ 62,535 4 $ 125,500 $ 70,688 5 $ 147,100 $ 78,848 6 $ 168,700 $ 87,000 PART 1, LINE 3C THE MAXIMUM AMOUNT CHARGED TO PATIENTS DEEMED ELIGIBLE UNDER THE FAP FOR "EMERGENCY OR OTHER MEDICALLY NECESSARY CARE" IS THE AMOUNT THE INSTITUTION INITIALLY CONCLUDED A PATIENT CAN AFFORD TO PAY WHEN FINALIZING THE FAP APPLICATION. THIS AMOUNT IS DERIVED BY CALCULATING A PATIENT'S HOUSEHOLD "NET MONTHLY INCOMEDEDUCTING THE TOTAL AMOUNT OF ROUTINE MONTHLY BILLS. THE AMOUNT REMAINING IS WHAT WE CONSIDER THE PATIENT CAN PAY EACH MONTH. IF THE PATIENT'S HOUSEHOLD MONTHLY ROUTINE BILLS ARE MORE THAN OR EQUAL TO "NET MONTHLY INCOME", THE INSTITUTION ACCEPTS WHATEVER THE PATIENT'S INSURANCE PAYS AS PAYMENT IN FULL, (THE PATIENT WOULD NOT HAVE TO PAY ANYTHING OUT-OF-POCKET); UNLESS THE PATIENT HAS ASSETS SUCH AS A SECOND HOME, STOCKS, CERTIFICATE OF DEPOSITS, LARGE SAVINGS OR ANY OTHER ASSETS EXCLUDING RETIREMENT AND EDUCATION ACCOUNTS. PATIENTS WITH LARGE AMOUNTS OF ASSETS WHOSE ROUTINE MONTHLY BILLS ARE GREATER THAN THEIR "NET MONTHLY INCOME" MAY BE ELIGIBLE FOR REDUCED TIME AND PAYMENT ARRANGEMENT AND WOULD MAKE MONTHLY PAYMENTS (12 TO 18 MONTHS) TO PAY OFF THE AMOUNT THE INSTITUTION DETERMINED THEY CAN AFFORD TO PAY. ONCE THE FAP APPLICATION IS FINALIZED AND A PATIENT IS DEEMED ELIGIBLE TO PAY NOTHING OR A REDUCED TIME PAYMENT, THIS AGREEMENT IS EFFECTIVE FOR ONE YEAR AND INCLUDES BALANCES THE PATIENT HAD OUTSTANDING. ALL PATIENTS ARE ADVISED OF MSK'S FAP, BUT AGAIN THE DETERMINATION IS ONLY DOCUMENTED IF THE PATIENT APPLIES FOR THE ASSISTANCE. PART I, LINE 7G MEMORIAL SLOAN KETTERING HAS CONSISTENTLY SET THE STANDARD OF CARE FOR PEOPLE WITH CANCER BY EMPHASIZING EARLY DETECTION, PRECISE DIAGNOSIS, AND INDIVIDUALLY TAILORED TREATMENT. THE HOSPITAL SUBSIDIZES CANCER SCREENING, TREATMENT, AND SUPPORT SERVICES TO FULFILL ITS MISSION AND TO HELP REDUCE CANCER HEALTH DISPARITIES AMONG MINORITY AND MEDICALLY UNDERSERVED POPULATIONS. MSK'S BREAST EXAMINATION CENTER OF HARLEM (BECH) PROVIDES BREAST AND CERVICAL CANCER SCREENING, COUNSELING, AND PATIENT FOLLOW-UP, AS WELL AS EDUCATIONAL PROGRAMS TO UNINSURED PATIENTS THROUGHOUT THE NEW YORK CITY AREA. BECH HAS A DEDICATED STAFF, INCLUDING A HEALTH EDUCATOR WHOSE ROLE IS TO INITIATE AND IMPLEMENT OUTREACH ACTIVITIES IN HARLEM AND THE SURROUNDING COMMUNITIES. SINCE ITS INCEPTION IN 1979, BECH HAS HAD MORE THAN 245,148 VISITS, WITH 1,752 OF THOSE VISITS TAKING PLACE IN 2018. ALL SERVICES WERE PROVIDED AT NO OUT-OF-POCKET EXPENSE TO THE WOMEN WHO RECEIVED CANCER SCREENING AND FOLLOW-UP SERVICES. LOCATED IN HARLEM, THE RALPH LAUREN CENTER FOR CANCER CARE (RLC) OFFERS CANCER SCREENING AND TREATMENT SERVICES TO ITS MEDICALLY UNDERSERVED COMMUNITY. THE RLC, MADE POSSIBLE IN PART THROUGH A GIFT FROM THE POLO RALPH LAUREN CORPORATION, IS SOLELY OWNED AND MANAGED BY MSK. SINCE ITS INCEPTION, RLC HAS CONDUCTED MORE THAN 164,993 VISITS, OF WHICH APPROXIMATELY 9,791 OCCURRED IN 2018. RLC CONTINUES TO PROVIDE CARE TO INDIVIDUALS ON MEDICAID AND MEDICARE MANAGED CARE PROGRAMS. TO BETTER SERVE THE NEEDS OF DIAGNOSED PATIENTS, THE RALPH LAUREN CENTER HAS EXPANDED ITS NAVIGATION EFFORTS BY CREATING A MULTIDISCIPLINARY TEAM FOR EACH ONCOLOGIST, CONSISTING OF A CLINICAL NURSE NAVIGATOR AND LAY NAVIGATOR. BOTH NAVIGATORS ASSIST PATIENTS FROM THE TIME OF DIAGNOSIS TO COMPLETION OF TREATMENT AND BEYOND. THE CLINICAL NAVIGATOR FOCUSES ON MEDICAL ISSUES, WORKING WITH THE ONCOLOGIST TO ENSURE THAT PATIENTS UNDERSTAND THEIR DIAGNOSIS AND TREATMENT PLAN. THE LAY NAVIGATOR WORKS WITH THE PATIENTS TO ELIMINATE BARRIERS SUCH AS TRANSPORTATION AND LINKING PATIENTS TO SERVICES IN THE COMMUNITY AS DEEMED NECESSARY. TOGETHER THEY WILL ENSURE THAT THE PATIENTS HAVE THE BEST OUTCOME FROM DIAGNOSIS THROUGH SURVIVORSHIP. THE CENTER CONTINUES TO ASSESS INDIVIDUALS WHO ARE UNINSURED TO BETTER SERVE THEIR MEDICAL NEEDS. NEW PATIENTS ARE SCREENED BY A FINANCIAL NAVIGATOR WHO HELPS PATIENTS EITHER APPLY FOR MEDICAID IF THEY QUALIFY OR THE AFFORDABLE CARE ACT. TO-DATE THE CENTER HAS FINANCIALLY ASSESSED MORE THAN 2,000 PATIENTS. MEMORIAL SLOAN KETTERING'S PSYCHIATRY & BEHAVIORAL SERVICES DEPARTMENT OFFERS INPATIENT AND OUTPATIENT PSYCHOLOGICAL AND SOCIAL SUPPORT SERVICES TO PATIENTS, THEIR FAMILIES, AND CAREGIVERS. ALL MEDICAID OUTPATIENT VISITS AND INPATIENT ENCOUNTERS ARE SUBSIDIZED BY MSK, AS ARE UNREIMBURSED TIME AND EFFORT BY NURSES TO STAFF A SMOKING CESSATION CLINIC. APPROXIMATELY 1,440 PATIENTS AGREED TO PARTICIPATE IN TREATMENT BY THE NURSING STAFF DURING 2018, APPROXIMATELY $2.5M OF PHILANTHROPIC FUNDS WERE USED TO SUPPORT A SIGNIFICANT NUMBER OF THE DEPARTMENT'S OVERALL CLINICAL AND TRAINING ACTIVITIES. THE INTEGRATIVE MEDICINE SERVICE PROVIDES FREE CLINICAL CARE FOR INPATIENTS AND OUTPATIENTS. DURING 2018, THE SERVICE PROVIDED 15,382 TREATMENTS WITH A RELATED PERSONAL COST OF $1.5M. THE CLINICAL SERVICES PROVIDED INCLUDE MUSIC THERAPY, TOUCH THERAPY, ACUPUNCTURE, YOGA AND YOGIC BREATHING, MEDITATION, GUIDED IMAGERY, KARATE, AND DANCE THERAPY. A TOUCH THERAPY FOR CAREGIVERS' COURSE IS OFFERED FREE OF CHARGE TO ANY INPATIENT AND THEIR FAMILY MEMBERS ONCE PER MONTH. PART I, LINE 7, COL (F) THE BAD DEBT EXPENSE WAS NOT INCLUDED ON LINE 25 IN ACCORDANCE WITH GENERALLY ACCEPTED ACCOUNTING PRINCIPLES (GAAP). HOWEVER, THE AMOUNT OF BAD DEBT EXPENSE FOR 2018 WAS $35.1M. PART I, LINE 7 FINANCIAL ASSISTANCE REPRESENTS THE COST OF SERVICES PROVIDED TO PATIENTS WHO CANNOT AFFORD HEALTH CARE SERVICES DUE TO INADEQUATE RESOURCES AND/OR ARE UNINSURED OR UNDERINSURED. A PATIENT IS CLASSIFIED AS A FINANCIAL ASSISTANCE PATIENT IN ACCORDANCE WITH THE INSTITUTION'S ESTABLISHED POLICIES AND WHERE INSUFFICIENT PAYMENT FOR SUCH SERVICES IS ANTICIPATED. THE INSTITUTION CONSIDERS PATIENTS FOR FINANCIAL ASSISTANCE IF HOUSEHOLD INCOME IS LESS THAN 500% OF THE FEDERAL POVERTY GUIDELINES. SERVICES PROVIDED AS FINANCIAL ASSISTANCE ARE NOT REPORTED AS REVENUE. THE COSTS REPORTED IN THE TABLE ON LINE 7, WERE BASED ON VARIOUS SOURCES. FINANCIAL ASSISTANCE AND UNREIMBURSED MEDICAID AND MEDICARE COMMUNITY BENEFITS COST WERE BASED ON A COST TO CHARGE RATIO CALCULATION. THE TOTAL CHARGES ASSOCIATED WITH THESE PROGRAMS ARE MULTIPLIED BY A RATIO OF HISTORICAL EXPENSES TO CHARGES AS DERIVED FROM THE HOSPITAL'S NEW YORK STATE INSTITUTIONAL COST REPORT. THE COSTS ASSOCIATED WITH A PORTION OF THE HEALTH PROFESSIONAL EDUCATION COMMUNITY BENEFIT ARE OBTAINED FROM THE STEP-DOWN OF COSTS PREPARED AS PART OF THE NEW YORK STATE INSTITUTIONAL COST REPORT. COST OF PROVIDING FINANCIAL ASSISTANCE AS CALCULATED PER THE ABOVE IS NET OF AMOUNTS RECEIVED FROM THE NEW YORK STATE BAD DEBT AND CHARITY CARE POOLS. TO ARRIVE AT THE AMOUNTS REPORTED IN THE TABLE ON LINE 7, ADDITIONAL STEPS AS OUTLINED BELOW WERE TAKEN. UNPAID COST OF GOVERNMENT-SPONSORED HEALTH CARE REPRESENTS THE ESTIMATED DIFFERENCE BETWEEN THE PAYMENTS MADE UNDER THE MEDICARE AND MEDICAID PROGRAMS AND THE INSTITUTION'S COST OF PROVIDING THESE SERVICES AS CALCULATED ABOVE. THE INSTITUTION SUBTRACTS ALL REVENUES RECEIVED FROM THE MEDICARE AND MEDICAID PROGRAMS TO DETERMINE THE COMMUNITY BENEFIT PROVIDED. RESEARCH COMMUNITY BENEFIT COSTS REPRESENT ALL COSTS FOR BASIC TRANSLATIONAL AND CLINICAL RESEARCH, SUPPORTED BY INSTITUTIONAL FUNDS, GOVERNMENTAL, AND OTHER NON-PROFIT ORGANIZATIONS. RESEARCH COSTS SUPPORTED BY PHILANTHROPIC FUNDS, TOTALING $128.3M ARE NOT INCLUDED IN THE NET COMMUNITY BENEFIT AMOUNT IN SCHEDULE H, PART I, LINE 7. THE INSTITUTION IS A PREEMINENT PROVIDER OF HEALTH TRAINING TO HEALTH PROFESSIONALS WHO DESIRE TRAINING IN THE SKILLS NECESSARY TO TREAT CANCER PATIENTS. THE INSTITUTION TRAINS PHYSICIANS, SCIENTISTS, MEDICAL STUDENTS, RADIOLOGY STUDENTS, NURSING STUDENTS, SOCIAL WORK STUDENTS AND INDIVIDUALS LOOKING TO CREATE A CAREER IN THE FIELD OF CANCER BIOLOGY. THE AMOUNTS REPORTED AS HEALTH TRAINING REPRESENT INSTITUTIONAL FUNDS, AS WELL AS COSTS IN EXCESS OF AMOUNTS REIMBURSED BY THIRD-PARTY PAYERS SUCH AS TRAINING GRANT REVENUES AND DIRECT MEDICAL EDUCATION PAYMENTS FROM THE MEDICARE PROGRAM. AS INDICATED EARLIER, MSK'S PSYCHIATRY & BEHAVIORAL SERVICES DEPARTMENT OFFERS INPATIENT AND OUTPATIENT PSYCHOLOGICAL SERVICES AND OTHER QUALIFYING SUBSIDIZED COMMUNITY BENEFIT PROGRAMS TO PATIENTS. SUBSIDIZED CANCER SCREENINGS ARE ALSO OFFERED AT THE INSTITUTION'S OTHER OUTPATIENT FACILITIES. THE COST ASSOCIATED WITH THESE PATIENTS' CARE ARE REPORTED IN THE TABLE ON LINE 7, BASED ON PATIENT CARE COST TO CHARGE. ALL SALARY EXPENSES RELATED TO OTHER SUBSIDIZED PATIENT CARE BY ATTENDING PHYSICIANS, CLINICAL AND RESEARCH FELLOWS AND NURSE PRACTITIONERS ARE ALSO REPORTED IN THE TABLE ON LINE 7G. PART II MSK ENGAGES IN AND SUPPORTS COALITION BUILDING ACTIVITIES THAT PROMOTE THE HEALTH OF THE COMMUNITIES THE INSTITUTION SERVES. STAFF MEMBERS ARE ENCOURAGED TO SHARE THEIR CLINICAL EXPERTISE AND EXPERIENCE WITH PARTNERING HEALTHCARE FACILITIES AND COMMUNITY ORGANIZATIONS. STAFF MEMBERS SERVE AND PARTICIPATE IN NUMEROUS COMMUNITY GROUPS INCLUDING THE AMERICAN CANCER SOCIETY, THE AMERICAN PUBLIC HEALTH ASSOCIATION, THE GREATER NEW YORK HOSPITAL ASSOCIATION, AND MANY HEALTH IMPROVEMENT ADVOCACY GROUPS FOR TYPES OF CANCER. ALTHOUGH THE SIGNIFICANT COST OF STAFF TIME DEVOTED TO THESE ACTIVITIES IS NOT QUANTIFIED BY THE CENTER, THE INSTITUTION CONSIDERS THESE EFFORTS TO COLLABORATE AND BUILD COMMUNITY RESOURCES TO BE OF SIZEABLE COMMUNITY BENEFIT. PART III, LINE 2 THE AMOUNT ON LINE 2 OF PART III IS THE ACTUAL 2018 BAD DEBT WRITE-OFF WHICH IS DERIVED BY TAKING THE GROSS CHARGES ASSOCIATED WITH THE PROVISIONS FOR BAD DEBTS AND MULTIPLYING BY A RATIO OF HISTORICAL EXPENSES TO CHARGES AS DERIVED FROM THE HOSPITAL'S NEW YORK STATE INSTITUTIONAL COST REPORT. A SEPARATE RATIO IS CALCULATED FOR EACH TYPE OF PATIENT CARE ACTIVITY: INPATIENT, OUTPATIENT, AND PHYSICIAN. PART III, LINE 3 PATIENTS CAN PURSUE FINANCIAL ASSISTANCE THROUGH MSK'S FINANCIAL ASSISTANCE PROGRAM. IF A PATIENT IS FOUND TO HAVE THE APPROPRIATE RESOURCES TO PAY FOR HEALTH SERVICES AND DOES NOT, OR CHOOSES NOT TO PARTICIPATE IN AVAILABLE HEALTH BENEFIT PROGRAMS, THE INSTITUTION WILL BEGIN COLLECTION PROCEEDINGS IN ACCORDANCE WITH THE INSTITUTION'S POLICY. ONCE DEEMED UNCOLLECTABLE, THE CHARGES ARE CLASSIFIED AS BAD DEBTS AND ARE CHARGED OFF AS SUCH. THE AMOUNT ON LINE 3, OF PART III, REFLECTS THE COST OF THESE ACCOUNTS AS CALCULATED BASED ON THE COST-TO-CHARGE RATIO METHODOLOGY DESCRIBED EARLIER. IN DETERMINING THE AMOUNT THAT REASONABLY COULD BE ATTRIBUTABLE TO PATIENTS WHO LIKELY WOULD QUALIFY FOR FINANCIAL ASSISTANCE UNDER THE INSTITUTION'S POLICY, THE INSTITUTION REVIEWED THE CASES THAT WERE CLOSED WITH AN "INCOMPLETE" STATUS IN THE FINANCIAL ASSISTANCE PROGRAM DURING 2014 THROUGH 2018. THE INSTITUTION THEN COMPARED THESE CASES AGAINST THE BAD DEBT WRITE-OFFS FROM 2018. PART III, LINE 4 THE INSTITUTION FOLLOWS GENERALLY ACCEPTED ACCOUNTING PRINCIPLES IN REPORTING ON BAD DEBT EXPENSES. THEREFORE, A DETAILED DESCRIPTION OF THE BAD DEBT POLICY IS NOT REQUIRED IN THE FOOTNOTES TO THE AUDITED FINANCIAL STATEMENTS. PART III, LINE 8 THE MEDICARE LOSS REFLECTS LOSSES FROM BOTH HOSPITAL AND PHYSICIANS' ACTIVITY. PHYSICIAN REVENUE IS SHOWN AS OTHER REVENUE ON THE MEDICARE COST REPORT. COSTS DISALLOWED BY THE MEDICARE PROGRAM, BUT WHICH ARE INCURRED IN PROVIDING CARE TO MEDICARE BENEFICIARIES HAVE BEEN INCLUDED. PART III, LINE 9B THE INSTITUTION DOES NOT PURSUE COLLECTIONS FROM PATIENTS APPLYING FOR FINANCIAL ASSISTANCE. IF, HOWEVER, COLLECTIONS WERE INITIATED THE EFFORT IS IMMEDIATELY SUSPENDED WHEN THE PATIENT APPLIES FOR FINANCIAL ASSISTANCE. IF THE PATIENT QUALIFIES FOR THE FAP WITH ZERO FEE PAYMENT, THE INSTITUTION ACCEPTS AS FULL SETTLEMENT ANY AMOUNT PAID BY THE INSURANCE CARRIER ON THE PATIENT'S BEHALF. ADDITIONALLY, IF A PATIENT QUALIFIES FOR A TIME PAYMENT PLAN (TPP) ALL OTHER CHARGES APART FROM THE AGREED TPP AMOUNT IS WRITTEN OFF AS FINANCIAL ASSISTANCE. FOR EXAMPLE, IF THE AGREEMENT CALLS FOR THE PATIENT TO MAKE AN ANNUAL PAYMENT OF $1,200 ($100 MONTHLY), THEN ALL OTHER CHARGES ACCRUING TO THE PATIENT ARE CANCELED AND WRITTEN OFF AS FINANCIAL ASSISTANCE. ANNUALLY, THE PATIENT'S CASE IS RE-EVALUATED AND ADJUSTMENTS MADE BASED ON CHANGING CIRCUMSTANCES. PART VI, LINE 2 THE CHNA IS THE MEANS BY WHICH THE INSTITUTION ASSESSES THE HEALTH NEEDS OF THE COMMUNITY - SEE PART V, SECTION B. PART VI, LINE 3 SINCE 1987, MSK HAS HAD A FINANCIAL ASSISTANCE PROGRAM IN PLACE TO ASSIST UNDERINSURED AND UNINSURED PATIENTS WHO ARE EXPERIENCING DIFFICULTIES MEETING THEIR FINANCIAL RESPONSIBILITIES TO MEMORIAL HOSPITAL AND ITS PHYSICIANS. FINANCIAL COUNSELORS WORK WITH PATIENTS AND INSURANCE COMPANIES - INCLUDING MEDICARE AND MEDICAID - TO HELP THE PATIENTS TO ACCESS SERVICES. THOSE WHO DO NOT QUALIFY FOR PUBLICLY AVAILABLE HEALTH INSURANCE OR WHO ARE UNABLE TO PAY THEIR PORTION OF FEES ABOVE INSURANCE REIMBURSEMENT, MAY OBTAIN HELP THROUGH THE INSTITUTION'S FAP IF THEY ARE ELIGIBLE. THE PREMISE OF THE PROGRAM IS THAT ALL PATIENTS ARE EXPECTED TO CONTRIBUTE TO THEIR CARE BASED ON THEIR FINANCIAL ABILITY. THE FINANCIAL ASSISTANCE PROGRAM EMPLOYS SEVERAL STRATEGIES TO INCREASE PATIENT'S AWARENESS OF THE PROGRAM. DURING THE REGISTRATION PROCESS, FINANCIAL INTERVIEWERS EDUCATE PATIENTS ON THE VARIOUS PROGRAMS AVAILABLE TO THEM, INCLUDING GOVERNMENTAL PROGRAMS AND THE FINANCIAL ASSISTANCE PROGRAMS. MSK PERSONNEL SENDS THE FAP BROCHURE WITH THE INITIAL HOSPITAL BILL TO EVERY NEW PATIENT TO MAKE THEM AWARE OF THE CHARITY CARE/FINANCIAL ASSISTANCE PROGRAM. THE FAP IS ALSO MENTIONED IN EVERY PATIENT STATEMENT AND LETTER THAT IS SENT TO A PATIENT. FAP IS ALSO MENTIONED IN EVERY COLLECTION LETTER SENT TO PATIENTS BY THE COLLECTION AGENCIES. EVEN AFTER A PATIENT'S ACCOUNT IS SENT TO COLLECTIONS HE/SHE CAN STILL APPLY FOR FINANCIAL ASSISTANCE. IT IS NEVER TOO LATE TO APPLY FOR FINANCIAL ASSISTANCE AND RETROACTIVE FAP COVERAGE WOULD BE GIVEN IF A PATIENT IS DETERMINED ELIGIBLE FOR ASSISTANCE. INFORMATION ABOUT THE FINANCIAL ASSISTANCE PROGRAM IS ALSO AVAILABLE ON THE INSTITUTION'S WEBSITE AT WWW.MSKCC.ORG/FINANCIAL-ASSISTANCE OR BY CALLING OUR DEDICATED FINANCIAL ASSISTANCE LINE AT (212) 639-3810. PART VI, LINE 4 MSK'S INPATIENT HOSPITAL IS IN MID-MANHATTAN WITH ADDITIONAL OUTPATIENT TREATMENT CENTERS IN BROOKLYN, LONG ISLAND, WESTCHESTER COUNTY, AND NEW JERSEY. OUR PRIMARY CATCHMENT AREA ENCOMPASSES 23 COUNTIES ACROSS THE FIVE BOROUGHS OF NEW YORK CITY, LONG ISLAND, SOUTHERN NEW YORK STATE, NEW JERSEY, AND SOUTHWESTERN CONNECTICUT. A TOTAL OF 186,563 PATIENTS WERE SEEN AT MSK'S FACILITIES IN 2018, INCLUDING 167,527 PATIENTS FROM THE TRI-STATE AREA (NY, NJ, CT); 17,286 PATIENTS FROM OTHER PARTS OF THE UNITED STATES; AND 1,750 PATIENTS FROM OTHER COUNTRIES. THESE PATIENTS ACCOUNTED FOR 24,243 ADMISSIONS TO OUR HOSPITAL WITH 129,207 RELATED HOSPITAL VISITS AND 647,339 OUTPATIENT VISITS AT OUR COMBINED FACILITIES IN NEW YORK CITY AND THE REGION. PART VI, LINE 5 MSK'S MISSION IS TO LEAD IN THE PREVENTION, DIAGNOSIS, TREATMENT, AND CURE OF CANCER THROUGH PROGRAMS OF EXCELLENCE IN COST-EFFECTIVE RESEARCH, EDUCATION, OUTREACH AND PATIENT CARE. OUR CLINICAL RESEARCHERS HAVE DEVELOPED NUMEROUS CHEMOTHERAPY AND RADIATION THERAPY REGIMENS, SURGICAL METHODS, AND DIAGNOSTIC TECHNIQUES THAT ARE NOW CONSIDERED THE STANDARD OF CARE FOR PATIENTS AROUND THE WORLD. WE FOCUS ON MULTIDISCIPLINARY CARE, WHERE EXPERTS FROM MANY FIELDS OF MEDICINE COME TOGETHER TO DEVELOP THE BEST TREATMENTS FOR INDIVIDUAL PATIENTS AND FOR THE TREATMENT FOR PATIENTS WITH ALL TYPES OF CANCER. THIS HAS ALLOWED US TO BE AT THE FOREFRONT OF DEVELOPING TREATMENTS THAT ARE MORE EFFECTIVE AT TREATING CANCER WHILE AT THE SAME TIME SPARING MANY PATIENTS FROM THE MOST SERIOUS SIDE EFFECTS OF TREATMENT. OUR BASIC AND TRANSLATIONAL RESEARCHERS HAVE MADE MANY SIGNIFICANT CONTRIBUTIONS TO THE SCIENTIFIC COMMUNITY'S UNDERSTANDING OF CANCER BIOLOGY AND CANCER GENETICS AS WELL AS TO RELATED FIELDS -- CELL BIOLOGY, MOLECULAR BIOLOGY, STRUCTURAL BIOLOGY, DEVELOPMENTAL BIOLOGY, MOLECULAR PHARMACOLOGY AND CHEMISTRY, IMMUNOLOGY, COMPUTATIONAL BIOLOGY, AND DRUG DEVELOPMENT. GENES FIRST IDENTIFIED IN OUR LABORATORIES ARE NOW THE FOCUS OF INTENSE RESEARCH IN OTHER LABORATORIES AROUND THE WORLD. DRUGS, MONOCLONAL ANTIBODIES, AND OTHER AGENTS FIRST DEVELOPED IN OUR LABORATORIES HAVE GONE ON TO GAIN REGULATORY APPROVAL FOR TREATING PATIENTS WORLDWIDE. RECENT EXPANSION OF OUR LABORATORY SPACE HAS ALLOWED US TO GROW OUR RESEARCH EFFORTS SO THAT GOING FORWARD WE CAN CONTINUE TO MAKE DISCOVERIES THAT WILL CHANGE THE WAY THE WORLD UNDERSTANDS CANCER AND AID IN THE DEVELOPMENT OF BETTER TREATMENTS FOR CANCER PATIENTS EVERYWHERE. IN 2018, MEMORIAL SLOAN KETTERING SPENT $529.5M IN SUPPORT OF ITS RESEARCH MISSION OF WHICH $209.0M WAS SPONSORED BY GOVERNMENTAL AND OTHER NON-PROFIT ORGANIZATION, $128.0M FROM PHILANTHROPY AND $192.5M FROM THE INSTITUTION'S FUNDS. EDUCATION AND TRAINING ARE KEY COMPONENTS OF MEMORIAL SLOAN KETTERING'S MISSION AND IMPORTANT EXAMPLES OF HOW THE INSTITUTION MAKES CONTRIBUTIONS TO THE CARE AND TREATMENT OF CANCER PATIENTS FAR BEYOND ITS OWN WALLS THROUGH WORKFORCE DEVELOPMENT. OUR TRAINING, GRADUATE, AND CONTINUING EDUCATION PROGRAMS PREPARE PHYSICIANS, SCIENTISTS, NURSES, AND TECHNICIANS TO BE LEADERS IN THEIR CHOSEN FIELDS. THESE HEALTHCARE PROVIDERS CAN THEN TAKE THE EXPERTISE GAINED FROM WORKING WITH OUR SPECIALISTS TO OTHER HEALTHCARE INSTITUTIONS AROUND THE COUNTRY AND THROUGHOUT THE WORLD. MSK ALSO TRAINS GRADUATE STUDENTS AND POSTDOCTORAL RESEARCHERS WORKING IN MANY AREAS OF BASIC SCIENCE AND TRANSLATIONAL RESEARCH. WHEN THESE YOUNG SCIENTISTS COMPLETE THEIR TRAINING, THEY BRING THE SKILLS OBTAINED IN OUR LABORATORIES INTO THE ACADEMIC COMMUNITY AT LARGE AS WELL AS THE PRIVATE SECTOR. MSK SPONSORS SEVERAL PROGRAMS THAT GIVE MEDICAL STUDENTS, UNDERGRADUATES, AND HIGH SCHOOL STUDENTS THE OPPORTUNITY TO WORK AT THE INSTITUTION DOING CLINICAL AND LABORATORY RESEARCH. THROUGH THESE PROGRAMS, MEMORIAL SLOAN KETTERING STRIVES TO INCREASE THE PIPELINE OF SCIENTISTS AND PHYSICIANS WORKING IN ONCOLOGY. MSK'S OFFICE OF DIVERSITY PROGRAMS IN CLINICAL CARE, RESEARCH, AND TRAINING (ODP) PROVIDES FUNDING TO ENCOURAGE INTEREST IN PURSUING CAREERS IN THE FIELD OF ONCOLOGY FOR MEMBERS OF MINORITY GROUPS WHO ARE UNDERREPRESENTED IN MEDICINE AND WISH TO PARTICIPATE IN THE NATIONAL CANCER INSTITUTE'S MEDICAL STUDENTS SUMMER FELLOWSHIP PROGRAM. THE ODP ALSO COORDINATES A SIX-WEEK SUMMER EXPOSURE PROGRAM TO EXPOSE UNDERREPRESENTED MINORITY HIGH SCHOOL STUDENTS TO CAREERS IN MEDICINE AND RESEARCH. MEMORIAL SLOAN KETTERING UTILIZED $244.8M OF THE INSTITUTION'S RESOURCES DURING 2018 TO SUPPORT ITS EDUCATION AND TRAINING MISSION, WHICH WE SEE AS VITAL GIVEN OUR LEADERSHIP ROLE IN CANCER CARE TREATMENT AND RESEARCH. $44.5M OF THE AMOUNT WAS SPONSORED BY GOVERNMENTAL AND OTHER REVENUE SOURCES AND $200.4M FROM INSTITUTION'S GENERAL FUND. THE INSTITUTION HAS A BOARD FOR EACH OF THE SEVEN ENTITIES. AS OUTLINED IN SCHEDULE O, THERE IS A TOTAL OF 114 BOARD MEMBERS. MANY ARE MEMBERS OF MORE THAN ONE ENTITY'S BOARD AND THEREFORE ARE COUNTED MORE THAN ONCE. THE GOVERNING BODY IS COMPRISED OF INDEPENDENT BOARD MEMBERS FROM THROUGHOUT THE UNITED STATES. MSK DOES NOT EXTEND MEDICAL STAFF PRIVILEGES TO COMMUNITY-BASED PHYSICIANS. ALL PHYSICIANS ARE ON STAFF AND ARE EMPLOYEES OF MSK. IN ITS PURSUIT TO FURTHER IMPROVE PATIENT CARE, MEDICAL EDUCATION AND RESEARCH, THE INSTITUTION REINVESTS ANY SURPLUS FUNDS IN THE INSTITUTION'S POOL OF RESERVES. THESE RESERVES GENERATE INCOME TO SUPPORT FUTURE OPERATIONS AND RESTRICTED FUND SPENDING. BY PROVIDING FUNDING FOR OPERATIONS AND CAPITAL PROJECTS, IMPROVEMENTS TO PATIENT CARE, MEDICAL EDUCATION, AND RESEARCH ARE MADE POSSIBLE. PART VI, LINE 6 THE ORGANIZATION IS NOT PART OF AN AFFILIATED HEALTH CARE SYSTEM. PLEASE SEE THE SUMMARY SECTION OF THE 990, ATTACHMENT 1 THROUGH ATTACHMENT 4 FOR FULL DETAIL ON THE ORGANIZATION'S STRUCTURE. PART VI, LINE 7 NEW YORK STATE true RALPH LAUREN CENTER FOR CANCER & PREVENTION 1919 MADISON AVENUE New York NY 10035 020597827 501(C)(3) 1000000 SUPPORT OPERATIONS 1 STIPENDS 399 24208000 Form 990, Schedule I FOR THE YEAR 2018, THE AMOUNT IS FOR STIPENDS PAID TO 325 RESEARCH FELLOWS AND 74 GRADUATE SCHOOL STUDENTS. EDUCATION AND TRAINING INCLUDES CLASSROOM INSTRUCTION WITH HANDS-ON EXPERIENCE IN BOTH RESEARCH LABORATORIES AND CLINICAL CARE ACTIVITIES. THE AFOREMENTIONED GRANTEES ARE REQUIRED TO BE IN COMPLIANCE WITH ACADEMIC REQUIREMENTS. THIS INCLUDES DIRECT SUPERVISION AND DIRECTION BY PHYSICIANS AND RESEARCH INVESTIGATORS. DURING 2018 MSKCC PAID $1,000,000 TO THE RALPH LAUREN CENTER FOR CANCER CARE & PREVENTION (RLC) TO OFFSET OPERATING EXPENSES. THE BOARD HAS APPROVED RESOLUTIONS TO SUPPORT THE RALPH LAUREN CENTER UP TO $1,000,000 PER YEAR FROM 2017 - 2019. MANAGEMENT OF MSKCC MONITOR THE USE OF GRANT FUNDS BY PARTICIPATING IN THE GOVERNANCE PROCESS OF THE RALPH LAUREN CENTER. MSKCC HAD PETITIONED NEW YORK STATE TO ALLOW RLC TO BECOME A FUNCTION OF MSKCC. FINAL APPROVAL WAS GRANTED DURING THE FIRST QUARTER OF 2019. X X true true X X X X X true true false false false false false true true true JOSE BASELGA MD PHD PIC-CHIEF MED OFF. TO 9/13/18 1239494 0 409841 40000 43300 1732635 18000 MICHAEL P GUTNICK EXECUTIVE VP & CFO 996953 0 63014 40000 30267 1130234 18000 KATHRYN MARTIN CHIEF OPERATING OFFICER 1341683 0 33444 540000 46105 1961232 18000 MARK SVENNINGSON SVP FINANCE 639591 0 40174 40000 36620 756385 18000 CRAIG B THOMPSON MD PRESIDENT & CEO 1801838 0 383948 1026675 213891 3426352 348830 KERRY BESSEY SVP & CHIEF HR OFFICER 665466 0 52836 40000 35910 794212 18000 ERIC M COTTINGTON PHD SVP RESEARCH & TECHNOLOGY MGMT 633699 0 44473 40000 37530 755702 18000 FREDRICK GROVES EVP & HOSPITAL ADMINISTRATOR 603458 0 40735 31000 24037 699230 9000 JASON KLEIN SVP-CHIEF INVESTMENT OFFICER 1549962 0 33482 974476 43844 2601764 18000 CAROLYN B LEVINE ESQ DEPUTY GEN COUNSEL CORP SECTY 396324 0 10134 28514 31953 466925 5716 JORGE LOPEZ ESQ EVP GENERAL COUNSEL 895245 0 67999 31000 42767 1037011 9000 EDWARD MAHONEY SVP FACILITIES MGMT & CONST 717311 0 33763 40000 30639 821713 18000 AVICE MEEHAN SVP CH COMMUNICATION OFFICER 433140 0 12705 30386 31010 507241 7835 RICHARD K NAUM SVP DEVELOPMENT RETIRED 7/1/18 153255 57900 18000 8191 3708 241054 18000 PATRICIA C SKARULIS SVP-CHIEF INFORMATION OFFICER 687910 0 18000 40000 15934 761844 18000 EDWIN TALIAFERRO VP INTERNAL AUDIT & COMPLIANCE 0 0 121539 0 9635 131174 0 MARK BILSKY MD ATTENDING-DEPT OF NEUROSURGERY 1690372 0 19062 31000 41426 1781860 9000 JOSEPH DISA MD ATTENDING PLASTIC SURGERY 1610597 0 58919 31000 47325 1747841 9000 MARIO LEITAO MD ATTENDING SURGERY 1517049 0 22800 31000 37615 1608464 9000 JEFFREY DREBIN MD CHAIRMAN ATTENDING-SURGERY 2378068 0 79969 31000 41110 2530147 9000 BABAK MEHRARA MD CHIEF ATTENDING-SURGERY 1849250 0 14382 31000 37631 1932263 9000 DEBRA BERNS ESQ SVP & CHIEF RISK OFICER 412611 100000 1614 29020 9416 552661 0 KENNETH MANOTTI SVP DEVELOPMENT 480415 50000 40027 31000 20462 621904 0 JOAN MASSAGUE PhD DIRECTOR SLOAN-KETTERING INST. 946669 0 157112 31000 29988 1164769 9000 Supplemental Compensation Information SCHEDULE J, PART I, LINE 1A BUSINESS OR FIRST-CLASS TRAVEL IS ALLOWED FOR FLIGHTS GREATER THAN SIX CONTINUOUS HOURS FOR ANY EMPLOYEE NOT FUNDED BY FEDERAL GRANTS. EXCEPTIONS TO THE SIX HOUR RULE ARE REVIEWED ON AN INDIVIDUAL BASIS. ALL TRAVEL MUST BE APPROVED BEFORE ANY ARRANGEMENTS ARE MADE. MSKCC HAS AN ACCOUNTABLE TRAVEL POLICY AND THEREFORE, DOES NOT INCLUDE TRAVEL AS TAXABLE COMPENSATION. THE DUTIES TO BE PERFORMED BY OUR PRESIDENT REQUIRE HIM TO BE ON CALL AND TO PERFORM DUTIES AS AND WHEN APPROPRIATE DURING HIS OFF-DUTY PERIODS AS WELL AS DURING NORMAL OFFICE HOURS. AN EMPLOYMENT CONTRACT REQUIRES OUR PRESIDENT TO LIVE IN THE OFFICIAL RESIDENCE OWNED AND MAINTAINED BY THE INSTITUTION. THE CONTRACT REQUIRES OUR PRESIDENT TO USE THE RESIDENCE FOR INSTITUTIONAL PURPOSES, INCLUDING, BUT NOT LIMITED TO, MEETINGS WITH STAFF, DONORS AND POTENTIAL DONORS, VISITING PROFESSORS AND SCIENTISTS, AND OTHER PERSONS INVOLVED WITH THE AFFAIRS OF THE INSTITUTION, CONFIDENTIAL INTERVIEWS WITH MEMBERS AND PROSPECTIVE MEMBERS OF THE STAFF; AND FOR OTHER INSTITUTIONAL ACTIVITIES CONDUCTED DURING AND OUTSIDE OF NORMAL OFFICE HOURS. THE COST IS REPORTED AS COMPENSATION ON FORM 990 AND IS EXCLUDED FROM TAXABLE COMPENSATION IN ACCORDANCE WITH CODE SECTION 119. SCHEDULE J, PART I LINE 4A - INCLUDED IN FORM 990 IS SEVERANCE PAY: EDWIN TALIAFERRO, VP INTERNAL AUDIT & COMPLIANCE, OF $116,800. TERMINATED IN APRIL 2017. JOSE BASELGA, MD. PHD, PHYSICAN IN CHIEF & CHIEF MEDICAL OFFICER OF $289,900. TERMINATED IN SEPTEMBER 2018. LINE 4B - THE INSTITUTION MAINTAINS A NONQUALIFIED DEFERRED COMPENSATION PLAN WHICH IS USED FOR EMPLOYER CONTRIBUTIONS IN EXCESS OF THOSE ALLOWED BY THE RETIREMENT PLAN. LINE 7 - INCENTIVE PAY IS PROVIDED TO OFFICERS AND KEY EMPLOYEES BASED ON THEIR ACHIEVEMENT OF PRE-DETERMINED GOALS RELATING TO QUALITY OF CARE, PATIENT SAFETY, OPERATIONAL EFFICIENCY AND FINANCIAL PERFORMANCE. THE COMPENSATION COMMITTEE OF THE BOARD AUTHORIZES ALL EXECUTIVE BONUSES AND INCENTIVE PLANS ON AN ANNUAL BASIS. LINE 8 - AN EMPLOYMENT CONTRACT WAS ENTERED INTO AND SIGNED PRIOR TO EMPLOYMENT. A DORMITORY AUTHORITY OF THE STATE OF NEW YORK 146000293 649906RK2 2012-02-16 388814944 SEE PART VI false false false B DORMITORY AUTHORITY OF THE STATE OF NEW YORK 146000293 6499063Z7 2013-06-28 80000000 SEE PART VI false false false C DORMITORY AUTHORITY OF THE STATE OF NEW YORK 146000293 000000000 2016-04-28 110000000 SEE PART VI false false false D NEW JERSEY ECONOMIC DEVELOPMENT AUTHORITY 222045817 000000000 2016-09-09 145000000 SEE PART VI false false false A 9145000 0 389043483 0 9172031 0 2651698 0 0 92720595 284499159 0 2014 false true true true B 42000000 0 80000000 0 0 0 0 0 0 0 80000000 0 2013 true false true true C 7610507 0 110239999 0 0 0 155282 0 0 110009717 75000 0 2017 false false true true D 32625000 0 145000000 0 0 0 72861 0 0 144627139 300000 0 2018 false false true true A false false false true false 0.00000 0.00000 0.00000 false false 0.00000 false true B false false false true false 0.00000 0.00000 0.00000 false false 0.00000 false true C false false false true false 0.00000 0.00000 0.00000 false false 0.00000 false true D false false false true false 0.00000 0.00000 0.00000 false false 0.00000 false true A false false false true false false 0 false 0 false true B false false false true false false 0 false 0 false true C false true false false false false 0 false 0 false true D false true false false false false 0 false 0 false true A true B true C true D true PART I, COLUMN (F) DESCRIPTION OF PURPOSE 2012 & 2012-I SERIES BONDS - CUSIP #649906RK2: 2012 SERIES BONDS WERE USED TO CONSTRUCT AND EQUIP AN AMBULATORY FACILITY AND TO ADVANCE REFUND A PORTION OF THE 2003 SERIES BONDS ISSUED MAY 14, 2003. 2013 SERIES BONDS - CUSIP #6499063Z7: 2013 SERIES BONDS WERE USED TO CURRENT REFUND THE 2010 DASNY SERIES BONDS ISSUED 9/2/2010 2016 SERIES BONDS (DASNY) - CUSIP #000000000 2016 DASNY SERIES BONDS WERE USED TO CONSTRUCT/RENOVATE AND UPGRADE AND EQUIP VARIOUS FACILITIES. 2016 SERIES BONDS (NJEDA) - CUSIP #000000000 2016 SERIES (NJEDA) BONDS WERE USED TO CONSTRUCT AND EQUIP VARIOUS FACILITIES. 2017 SERIES BONDS - CUSIP #000000000: 2017 SERIES BONDS WERE USED TO CURRENT REFUND THE 2015 SERIES BONDS ISSUED JULY 16, 2015 AND CONSTRUCT VARIOUS FACILITIES. PART II LINE 3 - THE AMOUNT OF PROCEEDS ON PART II LINE 3 IS DIFFERENT FROM PART I COLUMN (E) BECAUSE PART II LINE 3 INCLUDES INVESTMENT INCOME AND GAINS/LOSSES. PART III LINE 3(D) - ANY MANAGEMENT CONTRACTS AND RESEARCH AGREEMENTS THAT MAY RESULT IN PRIVATE BUSINESS USE OF BONDS FINANCED PROPERTIES ARE REVIEWED FIRST BY IN-HOUSE STAFF WHO ARE KNOWLEDGEABLE OF AND RESPONSIBLE FOR THE FORM 990. OUTSIDE COUNSEL IS CONSULTED IF QUESTIONS ARISE. PART IV LINE 2 - THE 2012 SERIES BONDS REBATE CALCULATIONS WERE LAST PERFORMED ON FEBRUARY 16, 2017. THE 2013 SERIES BONDS REBATE CALCULATIONS ARE CURRENTLY BEING PERFORMED. A DORMITORY AUTHORITY OF THE STATE OF NEW YORK 146000293 000000000 2017-12-20 335567386 SEE PART VI false false false A 4000000 0 337296892 0 0 0 2262236 0 0 155915529 91432989 87686139 true false false true A false false false true false 0.00000 0.00000 0.00000 false false 0.00000 false true A false true false false false false 0 false 0 false true A true MS T LINDSTEN SEE PART V 219857 FAMILY EMPLOYMENT false MR I GUTNICK SEE PART V 106919 FAMILY EMPLOYMENT false KING STREET CAPITAL MANAGEMENT SEE PART V 742339 INVESTMENT MANAGEMENT FEES false JOSE BASELGA MD PHD SEE PART V 209476 MMPC false BUSINESS TRANSACTIONS INVOLVING INTERESTED PERSONS 1. DR. THOMPSON IS THE PRESIDENT OF THE INSTITUTE. HIS SPOUSE IS A LABORATORY MEMBER FOR SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH. HER COMPENSATION FOR 2018 WAS $219,857. 2. MR. MICHAEL P. GUTNICK IS THE EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER. HIS SON IS A FUND COORDINATOR IN THE DIVISION OF MEDICINE IN THE HOSPITAL. HIS SON'S TOTAL COMPENSATION FOR 2018 WAS $106,919. 3. MS. JAMIE NICHOLLS IS A BOARD MEMBER OF THE INSTITUTION. HER SPOUSE IS A CO-FOUNDER OF KING STREET CAPITAL MANAGEMENT. DURING 2018, THE CENTER PAID KING STREET $742,339 IN MANAGEMENT FEES. MSK gave a redemption notice at the end of 2018, and pursuant to standard redemption terms, will maintain a small and declining exposure to King Street throughout 2019 and into 2020. THE INSTITUTION INVESTED IN KING STREET PRIOR TO MS. NICHOLLS JOINING THE BOARD OF MEMORIAL SLOAN KETTERING CANCER CENTER. 4. Jose Baselga, M.D was the Physician in Chief and Chief Medical Officer of the Organization until September 2018. As of December 31, 2018, he was also 100% owner of Memorial Medical Care PC, a Section 501(c)(3) tax-exempt captive medical group . Memorial Medical Care PC provides home healthcare to the hospitals bone marrow transplant patients. The Section 501(c)(3) captive PC and the Hospital have a management agreement where there is no cost to the hospital for the service. The hospital provides and charges the captive PC for services rendered. The amount reported is the cost of such services provided to the Section 501(c)(3) captive PC. THE INDIVIDUALS LISTED WERE NOT A PARTY TO THE TRANSACTIONS. THERE IS NO SHARING OF THE INSTITUTION'S REVENUE. THE PURCHASES OF GOODS OR SERVICES BY THE INSTITUTION WERE MADE IN THE ORDINARY COURSE OF THE PROVIDER'S BUSINESS, AT COMMERCIALLY AVAILABLE RATES NORMALLY CHARGED TO OTHERS. X 259 7865351 MARKET VALUE false true false PART I EXCLUDED FROM THIS VALUE ARE PLEDGE PAYMENTS, MADE BY STOCK, TOTALING $5,073,926. PROMISES TO GIVE ARE REPORTED AT THE DATE THE INTENT IS MADE IN WRITING. PUBLICLY TRADED DONATED STOCK IS SOLD BY MERRILL LYNCH ON BEHALF OF MEMORIAL SLOAN-KETTERING CANCER CENTER AND ITS AFFILIATED ORGANIZATIONS. PART VI, LINE 2 FOR THE TAX YEAR 2018, THE FOLLOWING BUSINESS RELATIONSHIPS WERE REPORTED: 1. DIRECTORS ELLEN V. FUTTER, LOUIS V. GERSTNER JR. AND PETER J. SOLOMON 2. DIRECTORS NORMAN C. SELBY, STANLEY F. DRUCKENMILLER, ALEXANDER T. ROBERTSON AND OFFICER ERIC M. COTTINGTON PHD. 3. DIRECTORS ANTHONY B. EVNIN AND NORMAN C. SELBY 4. DIRECTORS ELLEN V. FUTTER AND RICHARD I. BEATTIE PART VI, LINES 6-7 THE ARTICLES OF INCORPORATION AND BY-LAWS WERE REVIEWED TO DETERMINE THAT THE SUPPORTED ORGANIZATIONS OUTLINED IN SCHEDULE-A HAVE THE POWER TO ELECT OR APPOINT MEMBERS TO THE BOARD OF THE SUPPORTING ORGANIZATIONS. MEMORIAL SLOAN-KETTERING CANCER CENTER, EIN 13-1924236, (MSK), IS THE SINGLE MEMBER OF THE PROSTATE CANCER CLINICAL TRIALS CONSORTIUM LLC, PCCTC, WHO HAS ELECTED TO BE TREATED AS A DISREGARDED ENTITY OF MSK FOR TAX PURPOSES AND MSKCC PROTON, INC. WHO HAS ELECTED TO BE TREATED AS A CORPORATION FOR TAX PURPOSES. MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES EIN 13-1624082, (MEM), IS THE SINGLE MEMBER OF MSKCC PROPERTIES LLC, WHO HAS ELECTED TO BE TREATED AS A CORPORATION FOR TAX PURPOSES. PART VI, LINE 11B PRIOR TO FILING THE RETURN, A REVIEW OF THE 990 WAS CONDUCTED BY THE SR. VP OF FINANCE AND THE CHIEF FINANCIAL OFFICER. IT IS THEN PRESENTED TO, AND REVIEWED BY, THE JOINT AUDIT COMMITTEE OF THE BOARD. THE JOINT AUDIT COMMITTEE REFERS THE FORM 990 TO THE FULL BOARD, AND A COPY IS PROVIDED TO EACH BOARD MEMBER FOR FURTHER REVIEW. MEMORIAL SLOAN-KETTERING'S FORM 990 IS REVIEWED BY OUTSIDE COUNSEL AND IS PREPARED IN CONJUNCTION WITH ERNST AND YOUNG, LLP. AND REVIEWED BY, THE JOINT AUDIT COMMITTEE OF THE BOARD. THE JOINT AUDIT COMMITTEE REFERS THE FORM 990 TO THE FULL BOARD, AND A COPY IS PROVIDED TO EACH BOARD MEMBER FOR FURTHER REVIEW. MEMORIAL SLOAN-KETTERING'S FORM 990 IS REVIEWED BY OUTSIDE COUNSEL AND IS PREPARED IN CONJUNCTION WITH ERNST AND YOUNG, LLP. PART VI, LINE 12C MSKs conflict of interest program during 2018 was based on the following three policies for Memorial Sloan Kettering Cancer Center, Memorial Hospital for Cancer and Allied Diseases and Sloan-Kettering Institute for Cancer Research: 1. Policy on Financial Conflict of Interest and Conflict of Commitment (Individual COI Policy) A. The Individual COI Policy applied to (i) employed physicians and scientists with academic appointments; (ii) fellows and postdoctoral researchers; (iii) administrative employees with authority to make purchasing decisions or who are otherwise able to bind or negotiate on behalf of MSK; (iv) designated individuals, including non-employees, who are senior or key personnel undertaking Public Health Service-funded research; and (v) employees and non-employees whose jobs include the design, conduct or reporting of research or whose job functions or committee membership give them the authority to influence purchasing decisions. B. Upon becoming covered by the Individual COI Policy, annually thereafter and as interests arise, an individual was required to disclose financial interests and outside activities that reasonably appear to be related to the individuals institutional responsibilities. C. Depending on the circumstances, disclosures were reviewed by either the Chair of the Conflict of Interest Advisory Committee (COIAC) and the Compliance Officer or their designee(s), or by the entire COIAC, to determine whether financial conflicts of interest existed. D. When a financial conflict of interest was identified, the Chair of the COIAC, the Compliance Officer or the entire COIAC determined how to address it, including by eliminating the interest or implementing a management plan. Management strategies included disclosure, recusal or other limitation of role, and independent oversight. 2. MSK Policy on Institutional Financial Conflicts of Interest (Institutional COI Policy) A. The Institutional COI Policy applied to institutional financial interests and financial interests of three key executives - the President of MSK, the Physician-in-Chief of Memorial Hospital for Cancer and Allied Diseases and the Director of the Sloan-Kettering Institute for Cancer Research (Key Executives). The policy required institutional and Key Executive financial interests to be reported to the Office of General Counsel (OGC). B. OGC was responsible for determining whether the financial interest was related to research or purchasing decisions; if so, the policy required determination of whether an institutional financial conflict of interest existed, i.e., whether the interest had the potential to directly and significantly affect the design, conduct or reporting of research or the outcome of purchasing decisions, to be made at the Board of Managers (Board) level. C. The policy required any institutional financial conflict of interest to be eliminated or managed (and, in some cases, reduced). Management strategies included recusal of the applicable Key Executive from decision-making regarding the arrangement and disclosure to relevant personnel to implement the recusal; disclosure of the interest in relevant publications, presentations, consent forms and educational materials; and independent clinical oversight by a disinterested senior personnel member or committee. 3. Conflict of Interest Policy (Board COI Policy) A. This policy required covered individuals, including officers and Board members, to disclose financial interests annually and on an ongoing basis. Other entities in the same tax-exempt group had overlapping officers and Board members as described in Schedule O; such persons reported financial interests through this or related process. B. The policy required the Board or an authorized committee to determine whether any disclosed interest gave rise to a conflict of interest. C. If it was determined that a conflict of interest existed with respect to a transaction or arrangement, the policy required, prior to authorizing the transaction or arrangement, determination by the Board or committee that authorizing the transaction or arrangement was in MSKs best interests, and that it was fair and reasonable to MSK. The covered individual with the conflict could make a presentation to the Board or committee, but could not participate in or influence the discussion of, or vote on, the proposed transaction or arrangement. The existence and resolution of any conflict of interest, along with associated determinations made and votes taken, were required to be documented in writing. D. For any approved transaction or arrangement that involved a conflict of interest, a conflict management plan could be implemented if doing so was in the best interests of MSK. Management plans could require disclosure, recusal or other limitation of role, independent oversight and confidentiality. MSK's conflict of interest program provides for monitoring and enforcement of compliance its conflict of interest policies. MSK conducted a focused review in 2018 and 2019, identifying certain instances of non-compliance with its policies. Since 2018, MSK has undertaken a process of reviewing and enhancing its policies and procedures and associated governance structures and practices, including: (1) creation of a designated Conflict of Interest Committee of the Board and (2) adoption of an updated Individual COI Policy, Institutional COI Policy and Board COI Policy. PART VI, LINE 15 MEMORIAL SLOAN-KETTERING CANCER CENTER (MSKCC) IS COMMITTED TO ENSURING THAT ITS EXECUTIVE COMPENSATION PROGRAM ADHERES TO THE ESTABLISHED STANDARDS OF REGULATORY COMPLIANCE AND BEST CORPORATE GOVERNANCE. THE MSKCC BOARD OF OVERSEERS AND MANAGERS HAS CHARGED THE JOINT HUMAN RESOURCES COMMITTEE (WHICH IS COMPOSED ENTIRELY OF INDEPENDENT BOARD MEMBERS WITH NO CONFLICTS OF INTEREST IN REGARD TO EXECUTIVE COMPENSATION) WITH MAKING ALL DECISIONS RELATED TO COMPENSATION FOR OFFICERS AND KEY EMPLOYEES. THE COMMITTEE REVIEWS THE TOTAL COMPENSATION OF THE INDIVIDUALS, INCLUDING BOTH CURRENT AND DEFERRED COMPENSATION, AND ALL EMPLOYEE BENEFITS, ON AN ANNUAL BASIS TO ENSURE THAT THE TOTAL COMPENSATION OF EACH OFFICER AND KEY EMPLOYEE IS REASONABLE. TO ASSIST IN THE COMPLETION OF ITS RESPONSIBILITIES, THE COMMITTEE ENGAGES THE SERVICES OF A NATIONALLY RECOGNIZED CONSULTING FIRM SPECIALIZING IN EXECUTIVE COMPENSATION FOR NOT-FOR-PROFIT HEALTHCARE ORGANIZATIONS. EACH YEAR THE COMMITTEE REVIEWS A COMPREHENSIVE REPORT PREPARED BY THE FIRM THAT INCLUDES MARKET DATA FOR FUNCTIONALLY COMPARABLE ROLES IN COMPARABLE ORGANIZATIONS (I.E., NOT-FOR-PROFIT ACADEMIC/RESEARCH MEDICAL CENTERS, ESPECIALLY THOSE SHARING A MISSION SIMILAR TO MSKCC, WITH OTHER HEALTHCARE SECTORS CONSIDERED ON A SELECTED BASIS) AND SUMMARIZES THE RELATIVE MARKET POSITION OF EACH EXECUTIVE'S TOTAL COMPENSATION. THE LAST REVIEW WAS DECEMBER 2017. THIS REVIEW SETS THE COMPENSATION FOR THE FOLLOWING YEAR. ADDITIONALLY, A SENIOR MEMBER OF THE CONSULTING FIRM ATTENDS COMMITTEE MEETINGS TO PROVIDE INFORMATION AND TO RESPOND TO QUESTIONS BY THE MEMBERS OF THE COMMITTEE. COMPENSATION LEVELS ARE ESTABLISHED CONSIDERING THE MARKET DATA, AN ASSESSMENT OF PERFORMANCE, AND OTHER BUSINESS JUDGMENT FACTORS, CONSISTENT WITH MSKCC'S EXECUTIVE COMPENSATION PHILOSOPHY. THE COMMITTEE'S DECISIONS ARE MADE IN THE BEST INTERESTS OF MSKCC AND ARE INTENDED TO ENSURE THE RECRUITMENT AND RETENTION OF KEY EXECUTIVE TALENT, CONSISTENT WITH THE MARKET PRACTICES OF OTHER NOT-FOR-PROFIT HEALTHCARE ORGANIZATIONS OF COMPARABLE SCOPE, MISSION AND COMPLEXITY. THE COMMITTEE'S REVIEW PROCESS FOLLOWS THE INTERMEDIATE SANCTIONS GUIDELINES FOR QUALIFYING FOR THE REBUTTABLE PRESUMPTION OF REASONABLENESS UNDER SECTION 4958 OF THE INTERNAL REVENUE CODE OF 1986: - THE COMPENSATION ARRANGEMENT IS APPROVED IN ADVANCE BY AN "AUTHORIZED BODY" OF THE APPLICABLE TAX EXEMPT ORGANIZATION (I.E, THE COMMITTEE, WHICH IS COMPOSED ENTIRELY OF INDIVIDUALS WHO DO NOT HAVE A CONFLICT OF INTEREST WITHIN THE MEANING OF THE REGULATIONS UNDER SECTION 4958). - THE AUTHORIZED BODY OBTAINS AND RELIES UPON "APPROPRIATE DATA AS TO COMPARABILITY" PRIOR TO MAKING ITS DETERMINATION, FOR WHICH COMPARABILITY DATA ARE PROVIDED AND ANALYZED BY SULLIVAN, COTTER AND ASSOCIATES, INC., A WELL-REGARDED EXPERT IN THE AREA OF HEALTHCARE COMPENSATION. - THE COMMITTEE ADEQUATELY DOCUMENTS THE BASIS FOR ITS DETERMINATION CONCURRENTLY WITH MAKING THAT DETERMINATION, AGAIN AS REQUIRED IN THE REGULATIONS. PART VI, LINE 19 OUR AUDITED FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST. IN ADDITION, THE FINANCIAL STATEMENTS CAN BE ACCESSED AT THE FOLLOWING WEB ADDRESS: WWW.DACBOND.COM. THE INSTITUTION HAS ENGAGED DAC BOND AS OUR INVESTOR RELATIONS AND DISCLOSURE/DISSEMINATION AGENT. THE INFORMATION AVAILABLE ON THIS WEB SITE INCLUDES AUDITED FINANCIAL STATEMENTS, QUARTERLY UNAUDITED FINANCIAL STATEMENTS AND THE BOND OFFERING STATEMENTS FOR ALL OUR DEBT ISSUES. IN ADDITION, COPIES OF THE GROUP 990 AND FILED 990T ARE ALSO AVAILABLE. THE POLICY ON FINANCIAL CONFLICT OF INTEREST AND COMMITMENT IS AVAILABLE TO THE PUBLIC UPON REQUEST AND IT ALSO CAN BE FOUND AT THE FOLLOWING INSTITUTIONAL WEB SITE: WWW.MSKCC.ORG. GOVERNING DOCUMENTS SUCH AS THE ARTICLES OF INCORPORATION AND CORPORATE BY-LAWS ARE NOT MADE AVAILABLE TO THE PUBLIC. PART VII, SECTION A THIS IRS FORM 990 IS FILED UNDER GROUP EXEMPTION NUMBER 3475, EIN 91-2154267. THE ATTACHED LIST REPRESENTS MEMBERS FROM THE GOVERNING BOARDS OF THE FOLLOWING AFFILIATED INSTITUTIONS THAT MAKE UP OUR EXEMPT GROUP: MEMORIAL SLOAN-KETTERING CANCER CENTER (MSK) EIN 13-1924236, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES (MEM) EIN 13-1624082, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (SKI) EIN 13-1624182, S.K.I. REALTY, INC. (SKR) EIN 13-3389586, LOUIS V. GERSTNER JR. GRADUATE SCHOOL OF BIOMEDICAL SCIENCES (SKG) EIN 20-2212588, MSK INSURANCE US, INC. (MVI) EIN 83-0363317, AND MSKCC PROTON INC.,(MPI) EIN 35-2397819. ALSO INCLUDED IN THE GROUP IS MSK PROPERTIES LLC. EIN 35-2464610 WITH MEMORIAL HOSPITAL BEING THE SOLE MEMBER. MEMORIAL SLOAN KETTERING BOARD OF MANAGERS: RICHARD I. BEATTIE IAN COOK STANLEY F. DRUCKENMILLER ANTHONY B. EVNIN ROGER W. FERGUSON WILLIAM E. FORD RICHARD N. FOSTER STEPHEN FRIEDMAN ELLEN V. FUTTER LOUIS V. GERSTNER, JR. JONATHAN N. GRAYER JAMIE GREGORY BENJAMIN W. HEINEMAN, JR. DAVID H. KOCH MARIE-JOSEE KRAVIS, VICE CHAIR OF THE BOARD JAMIE C. NICHOLLS, VICE CHAIR OF THE BOARD, NOT INDEPENDENT SEE SCHED. L JAMES G. NIVEN BRUCE C. RATNER CLIFTON S. ROBBINS, BOARD MEMBER & TREASURER ALEXANDER T. ROBERTSON JAMES D. ROBINSON III, BOARD MEMBER & HONORARY CHAIRMAN OF THE BOARD VIRGINIA M. ROMETTY NORMAN C SELBY, BOARD MEMBER & SECRETARY STEPHEN C. SHERRILL PETER J. SOLOMON JOHN R. STRANGFELD SCOTT M. STUART, CHAIR-ELECT OF THE BOARD CRAIG B. THOMPSON, M.D., BOARD MEMBER, PRESIDENT AND CHIEF EXECUTIVE OFFICER EMPLOYEE, NOT INDEPENDENT BOARD MEMBER DOUGLAS A. WARNER III, CHAIRMAN OF THE BOARD UNTIL DECEMBER 2018 PETER A. WEINBERG DEBORAH C. WRIGHT 31 TOTAL BOARD MEMBERS 29 INDEPENDENT BOARD MEMBERS MEMORIAL HOSPITAL BOARD OF MANAGERS: RICHARD I. BEATTIE, HONORARY CHAIRMAN OF THE BOARD IAN COOK STANLEY F. DRUCKENMILLER ANTHONY B. EVNIN ROGER W. FERGUSON WILLIAM E. FORD RICHARD N. FOSTER STEPHEN FRIEDMAN ELLEN V. FUTTER LOUIS V. GERSTNER, JR. JONATHAN N. GRAYER JAMEE Gregory BENJAMIN W. HEINEMAN, JR., VICE CHAIR OF THE BOARD DAVID H. KOCH MARIE-JOSEE KRAVIS JAMIE C. NICHOLLS, CHAIR OF THE BAORD JAMES G. NIVEN BRUCE C. RATNER CLIFTON S. ROBBINS, BOARD MEMBER & TREASURER ALEXANDER T. ROBERTSON JAMES D. ROBINSON III VIRGINIA M. ROMETTY NORMAN C SELBY, BOARD MEMBER & SECRETARY STEPHEN C. SHERRILL PETER J. SOLOMON JOHN R. STRANGFELD SCOTT M. STUART CRAIG B. THOMPSON, M.D., BOARD MEMBER, CHIEF EXECUTIVE OFFICER EMPLOYEE, NOT INDEPENDENT BOARD MEMBER DOUGLAS A. WARNER III PETER A. WEINBERG DEBORAH C. WRIGHT 31 TOTAL BOARD MEMBERS 30 INDEPENDENT BOARD MEMBERS SLOAN KETTERING INSTITUTE BOARD OF MANAGERS: RICHARD I. BEATTIE IAN COOK STANLEY F. DRUCKENMILLER ANTHONY B. EVNIN ROGER W. FERGUSON WILLIAM E. FORD RICHARD N. FOSTER STEPHEN FRIEDMAN ELLEN V. FUTTER LOUIS V. GERSTNER, JR., HONORARY CHAIRMAN OF THE BOARD JONATHAN N. GRAYER BENJAMIN W. HEINEMAN, JR. JAMEE GREGORY DAVID H. KOCH MARIE-JOSEE KRAVIS JAMIE C. NICHOLLS JAMES G. NIVEN BRUCE C. RATNER CLIFTON S. ROBBINS, BOARD MEMBER & TREASURER ALEXANDER T. ROBERTSON JAMES D. ROBINSON III VIRGINIA M. ROMETTY NORMAN C SELBY, BOARD MEMBER & SECRETARY STEPHEN C. SHERRILL PETER J. SOLOMON JOHN R. STRANGFELD SCOTT M. STUART CRAIG B. THOMPSON, M.D., BOARD MEMBER, CHIEF EXECUTIVE OFFICER EMPLOYEE, NOT INDEPENDENT BOARD MEMBER DOUGLAS A. WARNER III PETER A. WEINBERG DEBORAH C. WRIGHT 31 TOTAL BOARD MEMBERS 30 INDEPENDENT BOARD MEMBERS S.K.I. REALTY BOARD OF MANAGERS: RICHARD I. BEATTIE LOUIS V. GERSTNER, JR. JAMES G. NIVEN, PRESIDENT CLIFTON S. ROBBINS SCOTT M. STUART DOUGLAS A. WARNER III, CHAIRMAN OF THE BOARD, UNTIL DECEMBER 2018 6 TOTAL BOARD MEMBERS 6 INDEPENDENT BOARD MEMBERS GERSTNER GRADUATE SCHOOL BOARD OF MANAGERS: RICHARD I. BEATTIE ELLEN V. FUTTER LOUIS V. GERSTNER, JR., CHAIRMAN OF THE BOARD DAVID H. KOCH MARIE-JOSEE KRAVIS PETER J SOLOMON SCOTT M. STUART, EFFECTIVE APRIL 2018 CRAIG B. THOMPSON, M.D. BOARD MEMBER, PRESIDENT, EMPLOYEE, NOT INDEPENDENT BOARD MEMBER DOUGLAS A. WARNER III 9 TOTAL BOARD MEMBERS 8 INDEPENDENT BOARD MEMBERS MSK INSURANCE U.S. BOARD OF MANAGERS: DEBRA BERNS-EMPLOYEE NOT AN INDEPENDENT BOARD MEMBER KATHRYN MARTIN, DIRECTOR AND SECRETARY, EMPLOYEE NOT AN INDEPENDENT BOARD MEMBER STEPHEN C. SHERRILL, CHAIRMAN OF THE BOARD MARK SVENNINGSON, BOARD MEMBER AND PRESIDENT EMPLOYEE, NOT INDEPENDENT BOARD MEMBER JEFFREY P. JOHNSON, BOARD MEMBER AND VICE PRESIDENT MICHAEL P. GUTNICK, BOARD MEMBER AND TREASURER EMPLOYEE, NOT INDEPENDENT BOARD MEMBER 6 TOTAL BOARD MEMBERS 2 INDEPENDENT BOARD MEMBERS MSKCC PROTON INC., BOARD OF DIRECTORS: JOSE BASELGA MD PHD, EMPLOYEE NOT AN INDEPENDENT DIRECTOR, UNTIL SEPTEMBER 2018 MICHAEL P GUTNICK, EMPLOYEE NOT AN INDEPENDENT DIRECTOR 1 TOTAL DIRECTOR, 0 INDEPENDENT DIRECTORS PART VII, SECTION B AMOUNTS PAID TO INDEPENDENT CONTRACTORS INCLUDE AMOUNTS PAID TO SUBCONTRACTORS AS WELL AS REIMBURSABLE EXPENSES. PART XI RECONCILIATION OF NET ASSETS, OTHER NON-OPERATING (EXPENSE): CHANGE IN POSTRETIREMENT $114,966,000 PENSION SETTLEMENT (40,414,000) OTHER NON-OPER EXPENSE (20,713,889) TOTAL $ 53,838,111 PROSTATE CANCER CLINICAL TRIALS 1275 YORK AVE NEW YORK NY 10065 352506225 CANCER CARE DE 9974000 2251000 MSKCC RALPH LAUREN CTR FOR CANCER & PREVENTION 1919 MADISON AVE NEW YORK NY 10036 020597827 CANCER CARE NY 501( C)3 10 MSKCC true MEMORIAL MEDICAL CARE PC 1275 YORK AVENUE NEW YORK NY 10065 352491455 CANCER CARE NY 501( C)3 10 MSKCC true MEM INFECT DISEASE 1275 YORK AVE NY NY 10065 133278582 HEALTH CARE NY MEM RELATED 2819838 0 false 0 true 1.00000 MEM MEDICAL CONSULT 1275 YORK AVE NY NY 10065 133278550 HEALTH CARE NY MEM RELATED 8116583 0 false 0 true 1.00000 MEM NUTRITION GRP 1275 YORK AVE NY NY 10065 133278576 HEALTH CARE NY MEM RELATED 995 0 false 0 true 1.00000 MEM SOLID TUMOR GRP 1275 YORK AVE NY NY 10065 133278578 HEALTH CARE NY MEM RELATED 42653198 0 false 0 true 1.00000 MEM PULMONARY FUNC 1275 YORK AVE NY NY 10065 133304834 HEALTH CARE NY MEM RELATED 4143697 0 false 0 true 1.00000 MEM CARDIOPULMONARY 1275 YORK AVE NY NY 10065 133278552 HEALTH CARE NY MEM RELATED 5849400 0 false 0 true 1.00000 MSK RADIOLOGY GRP 1275 YORK AVE NY NY 10065 133375559 HEALTH CARE NY MEM RELATED 81314228 0 false 0 true 1.00000 MEM NUCLEAR MED 1275 YORK AVE NY NY 10065 133278580 HEALTH CARE NY MEM RELATED 8533456 0 false 0 true 1.00000 MEM RADIATION ONCOL 1275 YORK AVE NY NY 10065 133237927 HEALTH CARE NY MEM RELATED 28241110 0 false 0 true 1.00000 MEM PATHOLOGY GRP 1275 YORK AVE NY NY 10065 133365998 HEALTH CARE NY MEM RELATED 49800463 0 false 0 true 1.00000 MEM ANESTHESIOLOGY 1275 YORK AVE NY NY 10065 133367135 HEALTH CARE NY MEM RELATED 59531714 0 false 0 true 1.00000 MEM PEDIATRICS GRP 1275 YORK AVE NY NY 10065 133346908 HEALTH CARE NY MEM RELATED 10190627 0 false 0 true 1.00000 MEM NEUROLOGY GRP 1275 YORK AVE NY NY 10065 133399377 HEALTH CARE NY MEM RELATED 11336882 0 false 0 true 1.00000 MEM PSYCHIATRY GRP 1275 YORK AVE NY NY 10065 133430629 HEALTH CARE NY MEM RELATED 4680463 0 false 0 true 1.00000 MSK PHYS AT PHELPS 1275 YORK AVE NY NY 10065 133897156 HEALTH CARE NY MEM RELATED -1830 0 false 0 true 1.00000 MSK AT MERCY 1275 YORK AVE NY NY 10065 133954858 HEALTH CARE NY MEM RELATED 6241545 0 false 0 true 1.00000 MSK SURGERY GROUP 1275 YORK AVE NY NY 10065 134010372 HEALTH CARE NY MEM RELATED 158174435 0 false 0 true 1.00000 MSK HAUPPAUGE 1275 YORK AVE NY NY 10065 134059247 HEALTH CARE NY MEM RELATED 5592413 0 false 0 true 1.00000 INTERGRATIVE MED 1275 YORK AVE NY NY 10065 542092060 HEALTH CARE NY MEM RELATED 1060955 0 false 0 true 1.00000 MSK-REGIONAL NETWK 1275 YORK AVE NY NY 10065 020594889 HEALTH CARE NY MEM RELATED 15544025 0 false 0 true 1.00000 MSK BASKING RIDGE 1275 YORK AVE NY NY 10065 593801080 HEALTH CARE NY MEM RELATED 14228100 0 false 0 true 1.00000 MEM URGENT CARE GRP 1275 YORK AVE NY NY 10065 651263291 HEALTH CARE NY MEM RELATED 7330938 0 false 0 true 1.00000 MEM CLN GENETICS 1275 YORK AVE NY NY 10065 651263292 HEALTH CARE NY MEM RELATED 312207 0 false 0 true 1.00000 MEM DEVELOP CHEMO 1275 YORK AVE NY NY 10065 133278548 HEALTH CARE NY MEM RELATED 5940428 0 false 0 true 1.00000 MSK CLINIC PRACTICE 1275 YORK AVE NY NY 10065 510616510 HEALTH CARE NY MEM RELATED 13212566 0 false 0 true 1.00000 MEM CLINICAL PHY 1275 YORK AVE NY NY 10065 133278556 HEALTH CARE NY MEM RELATED 2241983 0 false 0 true 1.00000 MEM DERMATOLOGY GRP 1275 YORK AVE NY NY 10065 133278581 HEALTH CARE NY MEM RELATED 6911241 0 false 0 true 1.00000 MEM ENDOCRINE GRP 1275 YORK AVE NY NY 10065 133278583 HEALTH CARE NY MEM RELATED 3591314 0 false 0 true 1.00000 GASTROENTEROLOGY 1275 YORK AVE NY NY 10065 133278574 HEALTH CARE NY MEM RELATED 7921807 0 false 0 true 1.00000 MEM HEMATOLOGYLYMP 1275 YORK AVE NY NY 10065 133278575 HEALTH CARE NY MEM RELATED 20452111 0 false 0 true 1.00000 MSK HARRISON 1275 YORK AVE NY NY 10065 300831483 HEALTH CARE NY MEM RELATED 17086503 0 false 0 true 1.00000 MSK BERGEN 1275 YORK AVE NY NY 10065 611791803 HEALTH CARE NY MEM RELATED 1718339 0 false 0 true 1.00000 MSK MONMOUTH 1275 YORK AVE NY NY 10065 300937486 HEALTH CARE NY MEM RELATED 11327691 0 false 0 true 1.00000 PANAKEIA ENERGY 10000 MEMORIAL DR HOUSTON TX 77024 800891961 INVESTMENT DE MSK EXCLUDED UNDER 512 1252884 17746632 false -1333710 true 0.99223 BTS LIQUIDATING LLC 1430 BROADWAY NY NY 10018 262602952 INVESTMENT NY MSK EXCLUDED UNDER 512 -66554970 1286339 false 0 true 0.70000 CHARITABLE REMAINDER TRUSTS 239 N/A TWO SIGMA US ALL CAP 89 NEXUS WAY CAMANA BAY GRAND CAYMAN CJ KY1-9007 INVESTMENT CJ MSK C 13146621 105994044 1.00000 true false true false false false false false false false false false false false false true false false RALPH LAUREN CTR FOR CANCER & PREVENTION Q 3966839 COST RALPH LAUREN CTR FOR CANCER & PREVENTION B 1000000 COST MEMORIAL MEDICAL CARE PC Q 209476 COST